



US 20100095391A1

(19) **United States**(12) **Patent Application Publication**
Silver(10) **Pub. No.: US 2010/0095391 A1**(43) **Pub. Date: Apr. 15, 2010**(54) **REGULATION OF LIPID DROPLET
FORMATION BY MODULATION OF FIT1
AND FIT2 AND USES THEREOF****Publication Classification**(51) **Int. Cl.***A01K 67/00* (2006.01)*A61K 31/711* (2006.01)*A61K 31/7105* (2006.01)*A61K 39/395* (2006.01)*G01N 33/53* (2006.01)*A61P 3/04* (2006.01)(76) Inventor: **David L. Silver**, New York, NY
(US)



Correspondence Address:

AMSTER, ROTHSTEIN & EBENSTEIN LLP
90 PARK AVENUE
NEW YORK, NY 10016 (US)(52) **U.S. Cl. 800/13; 514/44 A; 514/44 R; 424/130.1;
435/7.21; 436/86**(21) Appl. No.: **12/448,840**(22) PCT Filed: **Jan. 8, 2008**(86) PCT No.: **PCT/US08/00258**

§ 371 (c)(1),

(2), (4) Date: **Nov. 20, 2009****Related U.S. Application Data**(60) Provisional application No. 60/880,279, filed on Jan.
12, 2007.(57) **ABSTRACT**

This invention provides methods of regulating fat storage in tissue by modulating the levels of Fibrate Induced Transcript 1 (FIT1) and/or Fibrate Induced Transcript 2 (FIT2), as well as diagnostic screens for disorders and conditions involving regulation of fat storage in tissue, assays for identifying agents that can regulate fat storage in tissue through modulating the levels of FIT1 and/or FIT2, and genetically altered mammals in which expression of FIT1 and/or FIT2 is altered in one or more tissue.







Figure 1A-1B

Figure 1C





Figure 1D

mFIT1

1 MERGPTVGAG LGAGTRVRAL IGCLVKVLLW VASALLYFGS EQAARLLGSP CLRRLYHAWL 60
61 AAVIFGPLL QEHVNSRTIF ASHGNEFNK FVNSAWGWC TFLGGFVLLV VFLATRRVAV 120
121 TARHLSRLW GAAVWRGAGR AFLIEDLTG SCFEPLPQGL LIHELPDRKS CLAAGHQWRG 180
181 YVSSHTFLL TFCCLMAEE AAVFAKYLAH GLPAGAPIRL VFLINVLLLG IWNFLLICTV 240
241 IYHQYTHKV VAAVGTFEAW YLYGSWYHQ PWSFGIPGHG LFPRSRSMRK HN

mFIT2

1 MEHLERCAWF LRGTLVRATV RRHLFWALVA AMLAGSVVKE LSPLPESYLS NKRNVLNRYF 60
61 VKLAWAWTVC LLLPFIALTN YLTGKTSLV LRRLSTLIVG TAIWYICTAL ENIEHYTGS 120
121 QYQPALEGI RQEHRSKQQC HREGGFHWGF DISGHSFILT FCAIMIVEEM AVLHEVKIDR 180
181 GHLHAAITT LVVALGFLT F WWMFLCTA VYFHDLTQKV FGIMFGLLGW YTYGYWYK 240
241 FSPGLPPQS CSLTKRDTY KK






Figure 2A-2B





Figure 3A

B



C




Figure 3B-3C




Figure 4A-4C




Figure 5A





Figure 5B





Figure 5B continued

S. cerevisiae
C. elegans
D. melanogaster
D. rerio
X. laevis
G. gallus
mFIT2
hFIT2
hFIT1
mFIT1
Clustal Consensus

Figure 5B continued




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11A-11B




Figure 12

A





Figure 13A-13B




Figure 14




Figure 15




Figure 16




Figure 17

REGULATION OF LIPID DROPLET FORMATION BY MODULATION OF FIT1 AND FIT2 AND USES THEREOF

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims the benefit of U.S. Provisional Application No. 60/880,279, filed Jan. 12, 2007.

STATEMENT OF GOVERNMENT SUPPORT

[0002] The invention disclosed herein was made with U.S. Government support under grant number P30-DK42196 from the National Institutes of Health. Accordingly, the U.S. Government has certain rights in this invention.

FIELD OF THE INVENTION

[0003] The invention is directed to methods of regulating fat storage in tissue by modulating the levels of Fibrate Induced Transcript 1 (FIT1) and/or Fibrate Induced Transcript 2 (FIT2), as well as to assays for identifying agents that can regulate fat storage in tissue through modulating the levels of FIT1 and/or FIT2. Preferred forms of the invention are directed to methods of reducing fat storage in tissue by decreasing the levels of FIT1 and/or FIT2, as well as to assays for identifying agents that can reduce fat storage in tissue through decreasing the levels of FIT1 and/or FIT2. The reduction of fat storage may aid in treatment of any disease that involves storage of cytoplasmic fat in droplets, such as obesity, diabetes, metabolic syndrome, fatty liver disease (steatosis and steatohepatitis), atherosclerosis, diabetic nephropathy, and hepatitis C infection. Also provided are diagnostic screens for disorders involving regulation of fat storage in tissue, which involve assaying the level of expression or activity of FIT1 and/or FIT2 in a blood, fluid, tissue or cell sample from a subject. The invention also provides genetically altered mammals in which expression of FIT1 and/or FIT2 is altered in one or more tissue.

BACKGROUND OF THE INVENTION

[0004] Throughout this application various publications are referred to in parenthesis. Full citations for these references may be found at the end of the specification immediately preceding the claims. The disclosures of these publications are hereby incorporated by reference in their entireties into the subject application to more fully describe the art to which the subject application pertains.

[0005] The ability to store energy in the form of triglyceride (TG) is conserved from *S. cerevisiae* to humans. Triglycerides are stored in the cytoplasm surrounded by a monolayer of phospholipid in distinct structures or organelles given numerous names such as lipid particles, oil bodies, adiposomes, eicososomes, and more commonly lipid droplets (1). Under normal physiological conditions, lipid droplets are involved in maintaining energy balance at the cellular and organismal level; but under conditions of extreme lipid droplet acquisition as in obesity, type II diabetes and cardiovascular diseases may ensue (2-6).

[0006] Recently, a great body of information has been generated revealing details of the composition and functions of many of the components of lipid droplets from *S. cerevisiae* (7), *drosophila* and mammalian cells (8-10). In mammalian cells, the catabolism of lipid droplets is a highly regulated process involving hormonal signals, droplet structural pro-

teins and lipases (2, 11, 12). While much has been learned about the components and catabolism of lipid droplets, the molecular mechanism of lipid droplet biogenesis remains unknown. The identification of many components of lipid droplets has not revealed obvious proteins that would be involved in their formation. A widely accepted model of lipid droplet biogenesis involves the budding of a single leaflet of the endoplasmic reticulum (ER) membrane with a newly forming core or "lens" of triglyceride (1). The evidence that cytosolic lipid droplets are derived from the ER is based on the findings that some lipid droplet associated proteins are also associated with the ER membrane, and in many instances lipid droplets have been shown to be in close association with the ER membrane (8, 13-16).

[0007] The occurrence of obesity is approaching epidemic proportions. Many of the diseases associated with obesity, namely diabetes, hepatic steatohepatitis and atherosclerosis are the result of inappropriate storage of fat. Thus, there is a need for means that can effectively reduce fat storage in human tissues.

SUMMARY OF THE INVENTION

[0008] The present invention provides methods of reducing fat storage in a subject by administering to the subject an amount of an agent that is effective to decrease the level of FIT1 and/or FIT2 in the subject.

[0009] The invention also provides methods of increasing fat storage in a subject by administering to the subject an amount of an agent that is effective to increase the level of FIT1 and/or FIT2 in the subject.

[0010] The invention also provides methods of screening for a disorder involving regulation of fat storage in tissue, the methods comprising determining the level of expression and/or activity of FIT1 and/or FIT2 in a blood, body fluid, tissue biopsy or cell sample from a subject, wherein alternation from normal of the level of expression or activity of FIT1 and/or FIT2 is indicative of a disorder involving regulation of fat storage in tissue.

[0011] The invention provides methods for screening for candidate agents that can reduce fat storage in tissue by determining whether or not an agent is effective to decrease the level of FIT1 and/or FIT2 in tissue or cells, wherein the method comprises contacting an agent with a cell line or tissue culture that expresses FIT1 and/or FIT2, and wherein reduction in expression and/or activity of FIT1 and/or FIT2 is indicative that the agent is a candidate agent for reducing fat storage in tissue.

[0012] The invention also provides methods for screening for candidate agents that can increase fat storage in tissue by determining whether or not an agent is effective to increase the level of FIT1 and/or FIT2 in tissue or cells, wherein the method comprises contacting an agent with a cell line or tissue culture that expresses FIT1 and/or FIT2, and wherein an increase in expression and/or activity of FIT1 and/or FIT2 is indicative that the agent is a candidate agent for increasing fat storage in tissue.

[0013] The invention also provides transgenic mammals in which FIT1 and/or FIT2 is overexpressed in one or more tissue. The invention further provides mammals that have been genetically altered so that expression of FIT1 and/or FIT2 is reduced in one or more tissue.

BRIEF DESCRIPTION OF THE FIGURES

[0014] FIG. 1A-1D. Analysis of FIT gene expression. (A) Total RNA (15 µg) from mouse tissues were subjected to

Northern blot analysis for murine FIT1 and FIT2 (mfit1 and mfit2). The tissues analyzed were as follows: 1, brain; 2, eye; 3, heart; 4, lung; 5, liver; 6, kidney; 7, adrenal; 8, spleen; 9, skeletal muscle; 10, white adipose; 11, brown adipose; 12, ovary; 13, testis; 14, stomach. Gapdh served as a positive hybridization probe. (B) Total cell lysates (80 μ g) from selected mouse tissues were subjected to Western blot analysis. The following tissues were analyzed: 1, lung; 2, heart; 3, skeletal muscle; 4, liver; 5, kidney; 6, adrenal gland; 7, white adipose tissue; 8, brown adipose tissue; 9, HEK293 cell positive control expressing FIT1 or FIT2. Calnexin served as a loading control. (C) A human RNA blot containing 2 μ g of poly(A) RNA per lane (FirstChoice Human Blot 1 from Ambion) was analyzed for both fit1 and fit2 (hfit1 and hfit2) expression in the following tissues: 1, brain; 2, placenta; 3, skeletal muscle; 4, heart; 5, kidney; 6, pancreas; 7, liver; 8, lung; 9, spleen; 10, colon. (D) Amino acid sequences of murine FIT1 (SEQ ID NO:3) and FIT2 (SEQ ID NO:4) and hydropathy plots. The horizontal line (slightly below +2) indicates the average hydrophobicity.

[0015] FIG. 2A-2B. Subcellular localization of FIT proteins. (A) Total post-nuclear membranes from mouse hearts were separated by continuous sucrose gradients. Fractions were subjected to Western blot analysis using antibody markers for the plasma membrane (Na K-ATPase), Golgi apparatus (Golgi 58 kDa), endoplasmic reticulum (calnexin), and FIT1 and FIT2. (B) Immunofluorescence localization of mouse FIT1-V5 and FIT2-V5 with the ER marker protein RFP-KDEL in HEK293 cells.

[0016] FIG. 3A-3C. Lipid droplet formation induced by FIT1 and FIT2. (A) HEK293 cells were transiently transfected with mouse FIT1, FIT2, or DGAT1 and lipid droplets were visualized using fluorescence microscopy by staining with BODIPY 493/503. (B) Triglyceride mass measurements from transiently transfected cells. M, mock transfected; F1, FIT1 transfected; F2, FIT2 transfected; D1, DGAT1 transfected; D2, DGAT2 transfected. Data are represented as the average $\pm$ SD. N=4 transfections per construct. (C) Triglyceride (TG) biosynthesis was determined by incubating transiently transfected HEK293 cells with the indicated constructs with 14 C glycerol for the indicated times. 14 C TG were separated using TLC analysis and quantified using phosphorimager analysis. DGATs served as positive controls for TG biosynthesis.

[0017] FIG. 4A-4C. shRNAi mediated knockdown of FIT2. NIH-3T3 or RAW246.7 cells were infected with lentivirus expressing shRNA sequence targeting murine FIT2 (FIT2shRNA), or control shRNA (contshRNA), or no lentivirus (control). (A) FIT2shRNA reduced lipid droplet formation during NIH-3T3 cell differentiation (days of differentiation are shown above image) as visualized by BODIPY493/503 staining. (B) Northern blot analysis shows that FIT2shRNA significantly reduced FIT2 mRNA levels compared to control or contshRNA infected cells. Expression of differentiation markers Apt and PPARGgamma, were not changed in FIT2shRNA treated cells compared to controls. (C) Western blot analysis shows that FIT2 protein is reduced in FIT2shRNA cells compared to controls.

[0018] FIG. 5A-5B. Sequence alignments of FIT orthologs in multiple species. (A) Cladogram generated with ClustalW showing the amino acid sequence homologies among FIT proteins. Accession numbers for each FIT ortholog is indicated next to the cladogram. (B) Amino Acid sequence alignment of some FIT orthologs shown in A. Alignment was

generated using the ClustalW algorithm. *S. cerevisiae* (YDR319-C, U32517, AAB64755) (SEQ ID NO:5), *C. elegans* (SEQ ID NO:7), *D. melanogaster* (SEQ ID NO:8), *D. rerio* (SEQ ID NO:11), *X. laevis* (SEQ ID NO:12), *G. gallus* (SEQ ID NO:13), mFIT2 (NM173397, NP775573) (SEQ ID NO:4), hFIT2 (XM371399, XP371399) (SEQ ID NO:2), hFIT1 (NM203402, NP981947) (SEQ ID NO:1), and mFIT1 (NMO26808, NP081084) (SEQ ID NO:3). Additional FIT sequences are shown in the Sequence Listing: *S. cerevisiae* (SCS3, NP011389, NC001139) (SEQ ID NO:6), *A. gambiae* (SEQ ID NO:9), *T. nigroviridis* (SEQ ID NO:10), *P. troglodytes* FIT2 (SEQ ID NO:14), *C. familiaris* FIT2 (SEQ ID NO:15), *B. taurus* FIT2 (SEQ ID NO:16), *P. troglodytes* FIT1 (SEQ ID NO:17), *C. familiaris* FIT1 (SEQ ID NO:18), and *B. taurus* FIT1 (SEQ ID NO:19).

[0019] FIG. 6. Fenofibrate induction of FIT1 and FIT2 in mouse liver and heart. Mice were fed fenofibrate (FF) as described in materials and methods. Total RNA (15 μ g) was subjected to Northern blot analysis. PPARalpha deficient mice (α -/-) served to demonstrate dependence of induction on PPARalpha. GAPDH served as a loading control.

[0020] FIG. 7. Titration of FIT expression plasmids in HEK293 cells. HEK293 cells were transiently transfected with the concentrations of plasmid DNA indicated for each construct shown above the Western blots. M, mock transfected; F1V5, mouse FIT1-V5; F2V5, mouse FIT2-V5; F1, mouse FIT1; F2, mouse FIT2. β -actin served as a loading control. The Western blot on the far left was probed with anti-V5 antibody, and blots to the right were probed with either anti-FIT1 or anti-FIT2 antibodies. 2.4 μ g of FIT1-V5 and 0.9 μ g of FIT2-V5 plasmid consistently gave similar expression levels and were used throughout this study.

[0021] FIG. 8. V5 epitope tagged FIT proteins produce lipid droplets. HEK293 cells were transiently transfected with FIT1-V5 and FIT2-V5 and lipid droplets were visualized by staining cells with BODIPY493/503. Control cells were mock transfected.

[0022] FIG. 9. FIT proteins cause lipid droplet formation in HeLa cells. HeLa cells were transiently transfected with mouse FIT1 and FIT2 and lipid droplets were visualized by staining cells with BODIPY493/503. Control cells were mock transfected.

[0023] FIG. 10. Expression analysis of genes involved in TG biosynthesis in FIT expressing cells. Northern blot analysis was performed on total RNA (15 μ g) from HEK293 cells transfected with mouse FIT1 or FIT2, and hybridized to human DNA probes that listed. Acl, citrate lyase; acc, acetyl-CoA carboxylase; fas, fatty acid synthase; gpat, glyceraldehyde phosphate acyltransferase; dgat2, diacylglycerol acyltransferase 2; dgat1, diacylglycerol acyltransferase 1; adrp, adipocyte differentiation related protein; fit, either human fit1 or fit2. β -actin was used as a loading control.

[0024] FIG. 11A-11B. Triglyceride biosynthesis and lipolysis assays in FIT2 knockdown cells. (A) Triglyceride synthesis measurements were performed at each time point during differentiation using 14 C glycerol and TLC analysis of triglyceride levels quantified by PhosphorImager analysis. Each time point contained 3 independent samples for each condition, and represented as mean $\pm$ std, $p < 0.001$. 3 independent samples were used for each condition, and represented as mean $\pm$ std, $p < 0.001$. (B) Lipolysis assays performed on cell lysates from NIH 3T3-L1 cells at day 4 and day 6 of differentiation. No differences were observed between control and shRNAcont and FIT2shRNA adipocytes.

[0025] FIG. 12. FIT1 is overexpressed in steatotic livers of ob/ob mice. RNA was isolated from wild-type and ob/ob mouse livers and adipose tissue and analyzed by Northern blot (20 µg of RNA per lane). Figure shows results from two independent mice per genotype. FIT1 is upregulated in both livers and adipose tissue of ob/ob mice compared to wild-type lean controls.

[0026] FIG. 13A-13B. FIT1 and FIT2 overexpression in mouse liver increases lipid deposition. (A) Control adenovirus injected mice had normal lipid deposition and liver morphology, while mice injected with the AdFIT1 and AdFIT2 adenovirus showed an accumulation of lipid in livers. Left column, Ad control; middle column, Ad FIT1; right column Ad FIT2. (B) FIT1 and FIT2 protein levels are increased in mouse livers injected with FIT1 and FIT2 adenoviruses compared to control injected mice.

[0027] FIG. 14. Rosiglitazone induces mFIT2 expression. NIH 3T3 preadipocytes were differentiated for the days indicated and treated or not treated with 1 µM rosiglitazone for 24 hrs. FIT2 mRNA was increased at all time points of differentiation by treatment with rosiglitazone (–, no rosiglitazone; +1 µM rosiglitazone). All lanes are from duplicate wells of cells.

[0028] FIG. 15. Lipid droplet formation in HEK 293 cells expressing wild-type or mutant FIT2. Mock, mock transfected control; WT, wild-type FIT2; FLL 157-9 AAA mutation, L164A mutation, E169A mutation.

[0029] FIG. 16. Western blot of FIT2 protein levels in HEK 293 cells expressing wild-type or mutant FIT2. M, mock transfected control; WT, wild-type FIT2; FLL, 157-9FL-LAAA mutation, L, L164A mutation, E, E169A mutation. All mutants and wild-type are c-terminally tagged with the V5 epitope.

[0030] FIG. 17. Human FIT2 expression produces lipid droplets. Overexpression of human FIT2 (hFIT2) and human FIT2 with a C-terminal V5 epitope tag (hFIT2-V5) in HEK293 cells resulted in numerous lipid droplets compared to mock transfected control cells.

DETAILED DESCRIPTION OF THE INVENTION

[0031] The invention provides a method of reducing fat storage in a tissue in a subject by administering to the subject an amount of an agent that is effective to decrease the level of FIT1 and/or FIT2 in the tissue in the subject. Preferably, the reduced fat storage involves reduced storage of cytoplasmic fat.

[0032] The subject can be a mammal, such as a mouse, rat, cat, dog, horse, sheep, cow, steer, bull, livestock, or monkey or other primate. Preferably, the subject is a human. The subject can have a disease involving storage of cytoplasmic fat in droplets. For example, the subject can have one or more of obesity, diabetes, metabolic syndrome, fatty liver disease, steatosis, steatohepatitis, atherosclerosis, diabetic nephropathy, and hepatitis C infection.

[0033] An examination of human tissues showed that FIT1 is primarily expressed in heart and skeletal muscle, while FIT2 is expressed in all tissues investigated (FIG. 1). Accordingly, agents that reduce FIT1 would be expected to decrease fat storage primarily in the heart and skeletal muscle, while agents that reduce FIT2 would be expected to decrease fat storage in a wide range of tissues including, for example, heart, lung, liver, kidney, brain and adipose tissue. Decreasing fat storage especially in adipose tissue would be expected to result in loss of body weight.

[0034] The methods can involve intervention at the level of DNA, RNA, and/or protein. For example, the presence or activity of FIT1 and/or FIT2 can be reduced by addition of an antisense molecule, a ribozyme, or an RNA interference (RNAi) molecule such as short hairpin RNA (shRNA), where the antisense molecule, ribozyme or RNAi molecule specifically inhibits expression of FIT1 or FIT2. The antisense molecule, ribozyme, or RNAi molecule can be comprised of nucleic acid (e.g., DNA or RNA) or nucleic acid mimetics (e.g., phosphorothionate mimetics) as are known in the art. Methods for treating tissue with these compositions are also known in the art. The antisense molecule, ribozyme or RNAi molecule can be added directly to the tissue in a pharmaceutical composition that preferably comprises an excipient that enhances penetration of the antisense molecule, ribozyme or RNAi molecule into the cells of the tissue. The antisense molecule, ribozyme or RNAi can be expressed from a vector that is transfected into the tissue. Such vectors are known in the art.

[0035] The presence or activity of FIT1 and/or FIT2 can be reduced by addition of an antibody or aptamer to the tissue, wherein the antibody or aptamer specifically binds to and reduces the activity of FIT1 or FIT2 in the tissue. The antibody or aptamer can be added directly to the tissue, preferably in a pharmaceutical composition comprising an agent that enhances penetration of the antibody or aptamer into the tissue. The antibody or aptamer can be encoded on a vector that is used to transfect the tissue. The antibody can be a polyclonal antibody or a monoclonal antibody. The antibody can be a humanized antibody. Preferably, the antibody is an internalizing antibody that is taken up by cells. The agent can be a small molecule.

[0036] The invention also provides a method of increasing fat storage in a tissue in a subject by administering to the subject an amount of an agent that is effective to increase the level of FIT1 and/or FIT2 in the tissue in the subject. The commercial compounds TZDs (e.g. rosiglitazone) can be used to increase FIT2. Increasing fat storage in tissues may be useful for treating malnutrition or for creating animal models for disease. In addition, since the anti-diabetic drugs TZDs also increase body weight and data presented herein show that they increase FIT2 in adipocytes, increased FIT2 expression in adipocytes might be part of the anti-diabetic effect of TZDs.

[0037] In different forms of the methods disclosed herein, the agent can target amino acids phenylalanine-leucine-leucine (FLL), corresponding to amino acids 157 through 159 of mouse FIT2 (mFIT2); amino acid leucine (L), corresponding to amino acid 164 of mFIT2; and/or amino acid glutamic acid (E), corresponding to amino acid 169 of mFIT2.

[0038] The invention also provides a method of screening for a disorder involving regulation of fat storage in tissue, the method comprising determining the level of expression and/or activity of FIT1 and/or FIT2 in a blood, body fluid, tissue biopsy or cell sample (e.g., skin cells) from a subject, wherein alternation from normal of the level of expression or activity of FIT1 and/or FIT2 in the sample is indicative of a disorder involving regulation of fat storage in tissue. For example, the assays can involve measuring the level of FIT1 and/or FIT2 mRNA expression, the level of FIT1 and/or FIT2 protein, or FIT1 and/or FIT2 protein activity levels. In different examples, the expression or activity of FIT1 and/or FIT2 is increased or decreased in comparison to the level found in subjects not having a disorder involving regulation of fat

storage. The disorder may be; for example, obesity, type 2 diabetes, metabolic syndrome, fatty liver disease (steatosis and steatohepatitis), atherosclerosis, diabetic nephropathy, hepatitis C infection, viral infection, or a disorder of cardiac, kidney, muscle or liver function.

[0039] The invention also provides a method for screening for a candidate agent that can reduce fat storage in tissue by determining whether or not the agent is effective to decrease the level of FIT1 and/or FIT2 in tissue or cells, wherein the method comprises contacting the agent with cells or tissue that express FIT1 and/or FIT2, and wherein reduction in expression and/or activity of FIT1 and/or FIT2 is indicative that the agent is a candidate agent for reducing fat storage in tissue.

[0040] The invention further provides a method for screening for a candidate agent that can increase fat storage in tissue by determining whether or not the agent is effective to increase the level of FIT1 and/or FIT2 in tissue or cells, wherein the method comprises contacting the agent with a cells or tissue that express FIT1 and/or FIT2, and wherein an increase in expression and/or activity of FIT1 and/or FIT2 is indicative that the agent is a candidate agent for increasing fat storage in tissue.

[0041] To screen for activators or inhibitors of FIT1 or FIT2, mammalian, insect, or yeast cells can be stably or transiently transfected with FIT1 or FIT2 gene under regulated control (such as the tet-on system) or constitutively active regulation. FIT1 and FIT2 expressing cells can be treated with molecules such as chemicals, proteins, nucleic acids (e.g., RNAi, antisense oligonucleotides (ASO), aptamers) and then or prior to treatment FIT1 and FIT2 expression is induced. Cells can be screened for fluorescence of lipid droplets (automated using a fluorimeter, facs sorter, microscope with camera, or manually visibly) by incubating cells with BODIPY 492/503 or Nile red, or other lipophilic dye (specific for neutral lipids such as oil-red-o). Alternatively, cellular neutral lipids can be screened by mass measurements of lipids (e.g., using TLC, mass spec, gas chromatography). Compounds that result in cells having enhanced fluorescent signals or neutral lipid mass will be considered as activators and further studied/verified. Compounds that result in cells having decreased fluorescent signals or neutral lipid mass will be considered as inhibitors and further studied/verified.

[0042] The following is a description of a specific example of a protocol that can be used to screen for small molecule inhibitors of FIT proteins. Infect NIH-3T3 L1 preadipocytes in 96 well plates with adenoviruses (1×10^8 particles per ml) expressing either FIT1 or FIT2 for 2 hours in normal growth media (DMEM). Remove virus and incubate cells in normal growth conditions (37 deg C., 5% CO₂ chamber) overnight. Next day, a single species of chemical will be added to individual wells and incubated for 24 hrs. The next day the presence of lipid droplets will be detected by adding 20 µg/ml of BODIPY 492/503 lipid stain for 20 minutes. Cells will be washed and imaged using a fluorimeter or fluorescent microscope. Drugs or agents that are effective in blocking lipid droplet formation are those that result in a decrease in fluorescence signal at a wavelength of 510-665 nm. Drugs or agents that are identified through this screen can be further analyzed for specificity toward FIT proteins and cytotoxicity.

[0043] In addition, mouse embryo fibroblasts isolated from FIT2 knockout embryos may also serve as a suitable model for the screening methods described herein. These fibroblasts can be stably or transiently transfected with FIT1 and/or FIT2

under the control of regulated or constitutively active promoters. These cells may have the advantage over other cell types because they do not have endogenous FIT2 or FIT1 expression and thus have lower "background" lipid droplet formation.

[0044] The cell culture screens for activator and inhibitors of FIT 1 and FIT2 can use, for example, human FIT1 and/or human FIT2 genes or mouse FIT1 and/or FIT2 genes.

[0045] The invention also provides a transgenic mammal in which FIT1 and/or FIT2 is overexpressed in one or more tissue. Preferably, fat storage is increased in the tissue compared to a wild-type mammal. For example, FIT1 and/or FIT2 can be overexpressed in the liver, heart, and/or skeletal muscle. As another example, FIT2 can be overexpressed in adipose tissue. The adipose tissue can be white and/or brown adipose tissue. The invention further provides a mammal that has been genetically altered so that expression of FIT1 and/or FIT2 is reduced in one or more tissue. Preferably, fat storage is reduced in the tissue in comparison to a wild-type mammal. For example, the mammal can be a FIT1 knockout or FIT1 conditional knockout or can be heterozygous for FIT1. The mammal can also be heterozygous for FIT2 or be a FIT2 conditional knockout. The mammal can be a non-human mammal such as a mouse.

[0046] This invention will be better understood from the Experimental Details that follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims that follow thereafter.

EXPERIMENTAL DETAILS

Materials and Methods

[0047] Reagents. FirstChoice Human Blot 1 (purchased from Ambion, cat#3140). Mouse total RNA was extracted from C57BL/6J mice and 15 µg of total RNA was used for Northern blot analysis. Rabbit polyclonal antibodies were raised against peptides corresponding to the C-terminal 15 amino acids of murine FIT1 and FIT2. Anti-V5 antibodies were purchased from Invitrogen Corporation. Full length FIT1 and FIT2 cDNAs were amplified from cDNA generated from mouse liver RNA using Thermoscript RT with polyDT primers (Invitrogen Corporation), followed by subcloning into pcDNA3.1 Directional TOPO (Invitrogen Corporation). BODIPY 493/503 and Nile Red were purchased from Invitrogen Corporation and used at 10 µg/ml.

[0048] Mice and gene arrays. 3 male wild-type mice and 3 male PPARalpha^{-/-} mice (purchased from Jackson labs, Bar Harbor, Me.) were fed a chow diet containing 0.2% fenofibrate (purchased from Sigma-Aldrich) for 7 days. After day 7, mice were euthanized and liver RNA extracted. RNA from the 3 wild-type mice and 3 PPARalpha^{-/-} mice were pooled in equal proportions to create 2 pools of RNA (wild-type versus PPARalpha^{-/-}). RNA was processed by standard Affymetrix protocols to screen the MG_430 2.0 mouse gene expression array.

[0049] Manual analysis of the gene array data revealed the presence of sequence 1451488 on the array (See Affymetrix data file at Gene Expression Omnibus) to be induced in the wild-type mice relative to the PPARalpha^{-/-} mice. 1451488 corresponds to gene bank accession number NM_026808. Using the BLAST search algorithm by NCBI, FIT2 (Affymetrix number 1454935 and accession number NM_173397)

and many other FIT orthologs were identified (FIG. 6). Sequence alignments were made using the publicly accessed program ClustaW.

[0050] Cell culture. HEK293, and HeLa cells were grown in DMEM 10% FBS. NIH-3T3 L1 adipocytes were a kind gift from Philip Scherer and grow and differentiated by standard methods (24).

[0051] Membrane fractionation. Mouse hearts were homogenized with 25 strokes using a dounce homogenizer in a buffer containing 10 mM Hepes pH7.4, 1 mM MgCl₂ and proteinase inhibitors (Complete EDTA free, Roche) followed by 3 brief sonication pulses on ice. Nuclei were removed by a 2000×g spin for 5 min and samples were loaded on the top of a continuous sucrose gradient and centrifuged in a SW41 rotor at 100,000×g for 18 hrs. The continuous sucrose gradient was prepared by mixing a 1.1 M sucrose solution made in the above buffer used for homogenization with a 0.58M sucrose solution made in the same buffer using a standard 12 ml gradient maker. After centrifugation, the top 3 fractions (800 µl each) were discarded because of visible cellular debris. All subsequent 800 µl fractions were collected for Western blot analysis.

[0052] Confocal immunofluorescence microscopy. HEK293 cells were transiently transfected with expression plasmids for mFIT1 and mFIT2 with C-term V5 tags and RFP-KDEL. Cells were fixed with 10% formalin for 15 minutes at room temperature, followed by permeabilization with 0.1% triton X-100. Cells were then blocked with Goat serum (5%) followed by consecutive incubations with anti-V5 antibody, and anti-mouse Alexa 488. After several post-antibody washes, cells were visualized by confocal microscopy using a BioRad Radiance 2000 Laser Scanning Confocal Microscope.

[0053] Human FIT expression. Human FIT2 cDNA (hFIT2) was amplified from the human hepatic cell line HepG2 using primers forward primer: 5'-CACCATGGAG-CATCTGGAGCGCTGCGAGTGGTTGTGCG-3' (SEQ ID NO:56) and reverse primer: 5'-TTATTTCTTGTAAC-TATCTTGCTTCAAATCAAAC-3' (SEQ ID NO:57). To produce a V5-epitope tagged version of hFIT2 (hFIT2-V5) the following reverse primer was used instead of the one described above: 5'-TTTCTTGTAAC-TATCTTGCTTCAAATCAAAC-3' (SEQ ID NO:58). The amplified hFIT2 cDNA was subcloned into pcDNA3.1 topo directional plasmid (Invitrogen Corp.). To test if hFIT2 and hFIT2-V5 can produce droplets, HEK293 cells were transfected with 2.4 µg of the above described plasmid expressing hFIT2 and stained 36 hr posttransfection with the lipid droplet stain BODIPY493/503. Lipid droplets were visualized by fluorescence microscopy.

[0054] TLC assays. Lipids were extracted from cells in culture using HIP: Hexane:isopropanol (3:2 V/V). Triglyceride and cholesterol ester mass was quantified using TLC according (21, 25). The TLC solvent system used was Hexane:Ethyl ether:Acetic acid (80:20:1).

[0055] Triglyceride biosynthesis and DGAT assays. Cells in culture were incubated with 7.5 µCi/mL of 14C-glycerol (Specific activity: 125-180 mCi/mmol, NEN-Amersham) for the indicated times, followed by extraction with HIP and separation by TLC as referenced above. Radioactive triglycerides were quantified using PhosphorImager analysis and represented as a rate of triglyceride production using arbitrary units obtained from PhosphorImager analysis.

[0056] Lipase activity assay. Total cellular lipase activity was measured using the established method of Holm and Osterlund in *Methods in Molecular Biology* 1999; 109, p 109-121.

[0057] Lentivirus shRNA. The following short hairpin RNA (shRNA) sequences (sense strand shown) were used to knockdown mouse FIT2 expression: shRNAcont, CAC-CGAATTCTCCGAACGTGTTCACGC-GAACGTGACACGTTCCGAGAA (SEQ ID NO:20); shRNAFIT2, (SEQ ID NO:21) CACCGCACCATGTTTG-TTTTGTGGCGAACCAACAAACCAAACATGGTGC.

[0058] Double stranded shRNA DNAs were used to generate lentiviruses using the U6 promoter driven BLOCK-iT Lentivirus RNAi expression system (Invitrogen Corporation). Knockdown of human FIT2 in HEK293 cells was performed by stably transfection using pEntryU6 vector (Invitrogen Corp). NIH-3T3 L1 pre-adipocytes and HepG2 cells were infected with an MOI of 10-50.

[0059] FIT2 mutations. FLL157-9 and single 164L and 169E residues were changed to alanines using standard PCR mutagenesis methods on the mouse FIT2 cDNA. Mutants were subcloned into pcDNA3.1 Topo Directional plasmid (Invitrogen corp.) for expression in HEK 293 cells. HEK 293 cells were transfected with 2 µg of DNA from each construct and cells were stained 36 hrs after transfection with BODIPY493/503 (10 µg/ml for 10 minutes) to visualize lipid droplets.

[0060] Mouse transgenic models of FIT1 and FIT2 overexpression: liver-specific expression. Transgenic mice were generated that overexpress mouse FIT1 and FIT2 specifically in liver using the murine albumin promoter (Albe/p vector, kind gift from Ronald Kahn, Harvard University). FIT1 and FIT2 located in pcDNA3.1 Directional vector were digested with HindIII-EcoRV and blunt ended using Klenow enzyme. A bovine growth hormone polyadenylation sequence was amplified by PCR from pcDNA3.1 using primers containing a 5' BamHI site and a 3' EcoRV site. This PCR product was digested with the aforementioned restriction enzymes and subcloned into Albe/p vector digested with the same enzymes and now designated Albe/p-BGH. This step introduced a necessary polyadenylation sequence. Next, the FIT1 and FIT2 blunt ended DNA fragment was subcloned into Albe/p-BGH digested with EcoRV yielding FIT1-, FIT2-Albe/p-BGH construct. This construct was then used to create transgenic mice at the Albert Einstein College of Medicine.

[0061] Mouse transgenic models of FIT1 and FIT2 overexpression: muscle-specific expression. Transgenic mice were generated that overexpress mouse FIT1 specifically in skeletal muscle using the muscle creatine kinase promoter (MCK pCK4800, kind gift from Rhonda Bassel-Duby, UT Southwestern Medical Center). The transgene was constructed by subcloning HindIII-EcoRV blunt ended FIT1 cDNAs into MCK pCK4800 digested with EcoRV to yield MCK-FIT1.

[0062] Mouse transgenic models of FIT1 and FIT2 overexpression: heart-specific expression. Transgenic mice were generated that overexpress mouse FIT1 specifically in cardiac myocytes using the alpha myosin heavy chain promoter enhancer vector (alpha-MHC vector, a kind gift of Ira Goldberg, Columbia University). To generate the transgene construct alpha-MHC vector was digested with SalI and made blunt using klenow enzyme. A HindIII-EcoRV blunt ended fragment of FIT1 was subcloned into the digested alpha-MHC vector to generate alpha-MHC-FIT1.

[0063] Mouse transgenic models of FIT1 and FIT2 overexpression: adipose-specific expression. Transgenic mice were generated that overexpress mouse FIT2 specifically in adipose tissue (white and brown adipose) using the Ap2 promoter/enhancer (kind gifts from Philip Scherer, Albert Einstein College of Medicine). To produce this transgene the 3'UTR Ap2 enhancer was digested with HindIII-EcoRV. FIT2 was digested with HindIII-EcoRV (from pcDNA3.1) and ligated into the vector containing the 3'UTR Ap2 enhancer to yield FIT2-3'UTR. The Ap2 promoter was digested with XmaI then made blunt, followed by digestion with Sall. FIT2-3'UTR was digested with HindIII and made blunt, then cut with Sall. The Ap2 digested fragment was then ligated into FIT2-3'UTR to make the final transgene Ap2-FIT2-3'UTR.

[0064] Mouse deficiency models for FIT1 and FIT2: FIT1 gene targeted mice. BAC recombineering methods were utilized according to the protocols found in Warming et al. (26) and publicly available at <http://recombineering.ncifcrf.gov/>. All materials obtained to perform BAC recombineering were obtained free of charge from NIH Division of Technology Development and Transfer Office (Phone: 301-435-5502). BAC RP23-186J4 (referred to as BAC J4) was purchased from Children's Hospital Oakland Research Institute. BAC J4 was electroporated into SW102 cells for further use in recombineering. Plasmid p1452 was used as template to add on 50 base pairs of homology flanking the NEO cassette located in p1452. The primer sequences are as follows: forward primer: CATTAGCCCCTCCTCAGCCTCCAGCA-GAGCAGACAGTTAGTGGGGAGGGGCCAT GGccgcatattcaataaccc (SEQ ID NO:22); reverse primer: TGTTTGCGCATTGAGCGGGATCGAGG-GAAGAGCCCGTGGCCTGGGATCCCATAA CTTCG-TATAGCATAC (SEQ ID NO:23). Plasmid p1452 has the sequence set forth in SEQ ID NO:54.

[0065] Purified PCR product (200 ng) was used to electroporate SW102 cells harboring BAC J4, and Kan and Chlor resistant colonies were selected for on plates (designated as BAC J4-NEO). Verification of correct targeting was carried out using the following pairs of PCR primers:

- (SEQ ID NO: 24)
1) FIT1F-TVP, GTTGACCGTCAGTCCTCAAACCTGGCCCTTGC;
(SEQ ID NO: 25)
PGK-R-TVP, GCTTGGCTGGACGTAACTCCTCTTCAGACC;
(SEQ ID NO: 26)
2) FIT1R-TVP, GAAAAGAAATCGGAGGAGACAGAGCCAGGCTGG;
(SEQ ID NO: 27)
BGH-F-TVP, GAACCAGCTGGGGCTCGACTAGAGCTTGCGG.

[0066] In addition, Southern blot analysis was performed to confirm proper targeting. BAC J4-NEO DNA was digested with NcoI and probed with a radiolabeled PCR fragment (300 bp fragment) generated using the following two PCR primers and BAC J4 as template:

NcoI-F: Acacaagttttgcacagacatagatgcagg (SEQ ID NO:28);

Nco-R: Caacttcacagcctagaatcatctgagaggagaacc (SEQ ID NO:29).

[0067] Following confirmation that exon 1 and exon 2 were replaced by the NEO cassette from plasmid p1452, a diphtheria toxin cassette with Amp resistance, DTA (kind gift of Chingwen Yang, Rockefeller University) was homologously

recombined into BAC J4-NEO. 50 bp homology arms were added by PCR to the DTA cassette using the following pair of primers:

- FIT-DTA-F: (SEQ ID NO: 30)
ACACAAGTTTTCACAGACATAGATGCAGGTAAATATACATAAGTAAGC
GAACAACTCCGCCGCGCGCTC;
FIT-DTA-R: (SEQ ID NO: 31)
CAACTTCACAGCCTAGAATCATCTGAGAGGAGAACCTCAATGGAGGAA
GAGTAACTTGGTCTGACAG.

[0068] PCR product (200 ng) was electroporated into SW102 cells harboring the BAC J4-NEO and colonies were selected that were Chlor, Kan and Amp resistant. Targeting of the DTA cassette was verified using the following two sets of PCR primer pairs:

- (SEQ ID NO: 32)
1) FIT3F-TVP, CAGGCTGCTCTTCAGGAGTATATCTGGGTTTC;
(SEQ ID NO: 33)
POLIIP1R-TVP, CCGGGAGCCACCTTCTTCCAAACGTCCTCCGG;
(SEQ ID NO: 34)
2) FIT3R-TVP, AGTTACAGACAATTGTGAGTTGCCATGTGGC;
(SEQ ID NO: 35)
AMP1F-TVP, CTGAGATAGGTGCCTCACTGATTAAGCATTGG.

[0069] 10 µg of BAC J4-NEO-DTA was cut with NotI to linearize and then electroporated into embryonic stem (ES) cells at the Columbia University Transgenesis facility. 45 ES cells were screened for homologous recombination using the following two PCR primers:

- (SEQ ID NO: 36)
FIT-ES1-TVP-F, GTACCCACAGTCACATCCATAGGACAATCC;
(SEQ ID NO: 37)
FIT-ES1-R, CTAAGTGTCTGCTCTGCTGGAGGCTGAGGAGG.

[0070] Targeted ES cells were then confirmed by Southern blot analysis using the NcoI probe as described above. The targeted D5 ES cell line was used to generate chimeric mice. The FIT1 Knockout mice are viable and fertile.

[0071] Mouse deficiency models for FIT1 and FIT2: FIT2 gene targeted mice. BAC recombineering methods were utilized according to the protocols found in Warming et al. (26) and publicly available at <http://recombineering.ncifcrf.gov/>. All materials obtained to perform BAC recombineering were obtained free of charge from NIH Division of Technology Development and Transfer Office (Phone: 301-435-5502). BAC RP23-36P22 (referred to as BAC P22) was purchased from Children's Hospital Oakland Research Institute. BAC P22 was electroporated into SW105 cells for further use in recombineering to specifically delete exon2. Plasmid p1452 was used as template to add on 50 base pairs of homology flanking the NEO cassette located in p1452. The primer sequences are as follows:

pL452FIT2a-F, (SEQ ID NO: 38)
 GCTCAGAGGAGGCAGACATGGCAGATGTTGCTGTATCTGGCCTAATGAAC
 ccgatcatattcaataaccc;
 pL452FIT2a-R, (SEQ ID NO: 39)
 ACGTGGGAATCCTATTAGCCATTGTCTCTGTCCCTATGCTCTTCTTT
 ataacttcgtatagcatac.

[0072] Purified PCR product (200 ng) was used to electroporate SW105 cells harboring BAC P22, and Kan and Chlor resistant colonies were selected for on plates (designated as BAC P22-NEO). Verification of correct targeting was carried out using the following pairs of PCR primers:

(SEQ ID NO: 40)
 1) FIT2-TVP1c-F, TAAGAATAGAGTGTAAGGGTGGTAGTTGTTCC;
 (SEQ ID NO: 25)
 PGK-R-TVP, GCTTGGCTGGACGTAACTCCTCTTCAGACC;
 (SEQ ID NO: 41)
 2) FIT2-TVP1d-F, CCTTCATCCTTCCCACTCGTAGTGGCTGGTC;
 (SEQ ID NO: 27)
 BGH-F-TVP, GAACCAGCTGGGGCTCGACTAGAGCTTGCGG.

[0073] Following confirmation that exon 2 were replaced by the NEO cassette from plasmid p1452, a diphtheria toxin cassette with Amp resistance, DTA (kind gift of Chingwen Yang, Rockefeller University) was homologously recombined into BAC P22-NEO. 50 bp homology arms were added by PCR to the DTA cassette using the following pair of primers:

FIT2-DTA-F, (SEQ ID NO: 42)
 ACAGTCCCAGCTCCCATGGCACTCCTCACTGTAATATAACTCGCCGATG
 gaacaactccgcgcgcgcgctc;
 FIT2-DTA-R, (SEQ ID NO: 43)
 GCTGGCCTGGAACTCACTTTATAGAGAGGGCTGGTTTGAACCTGTGTT
 Ggagtaaaacttggtctgacag.

[0074] 200 ng of PCR product was electroporated into SW102 cells harboring the BAC P22-NEO and colonies were selected that were Chlor, Kan and Amp resistant. Targeting of the DTA cassette was verified using the following two sets of PCR primer pairs:

(SEQ ID NO: 44)
 1) FIT2-TVP5-F, CTTCTGTCACACTAGTCAAGCATCCTACCAAC;
 (SEQ ID NO: 33)
 POLIIP1R-TVP, CCGGGAGCCACCTTCTTCTCCAACCGTCCCGG;
 (SEQ ID NO: 45)
 2) FIT2-TVP7-R, CTATTTTGAACAGGATCTCTTACGTGACCC;
 (SEQ ID NO: 35)
 AMP1F-TVP, CTGAGATAGGTGCCTCACTGATTAGCATTGG.

[0075] 10 µg of BAC P22-NEO-DTA was cut with NotI to linearize and then electroporated into ES cells at the Columbia University Transgenesis facility. 48 ES cells were screened

for homologous recombination by Southern blot analysis. ES cell DNA was digested in 96 well plates with NcoI and probed with a 300 bp fragment, which is the same fragment replaced by the DTA cassette on the P22 BAC. Wild-type alleles yielded a 2.8 kb fragment and targeted alleles resulted in the appearance of a 3.5 kb fragment.

[0076] The targeted A3, ES cell line was used to generate chimeric mice. It was been determined that deletion of FIT2 results in embryonic lethality and therefore conditional FIT2 targeted mice were generated as described below.

[0077] FIT2 Conditional targeted mice. Based on the finding described herein that gene targeted deletion of FIT2 results in embryonic lethality, BAC recombineering was used to produce a "foxed" allele of FIT2 to conditionally knock it out in adult mice.

[0078] The same BAC, P22 was used for generating an engineered targeting vector. For insertion of a single loxP site within intron 1 upstream of exon 2, pL451 was PCR amplified to introduce 50 bp homology arms to this region using the following primers (uppercase letters correspond to vector sequences of pL451):

FIT2pL451a-F, (SEQ ID NO: 46)
 taatgaaccaggagcccagcagcctggcagccaattgtttagggtagc
 GATATCGAATTC;
 FIT2pL451a-R, (SEQ ID NO: 47)
 gaaaaaaagaagaagaagcagcagcctttagttcaagctacaagac
 AGTGGATCCACC.

Plasmid p1451 has the sequence set forth in SEQ ID NO:55.

[0079] 200 ng of PCR product was electroporated into SW105 cells harboring the P22 BAC and cells were selected for kanamycin resistance yielding P22-NEO. Homologous recombination was verified using the following primers:

(SEQ ID NO: 48)
 1) FIT2-TVPC1-R, accacatggtggtcataaccatctgtcatg;
 (SEQ ID NO: 27)
 BGH-F-TVP, GAACCAGCTGGGGCTCGACTAGAGCTTGCGG;
 (SEQ ID NO: 49)
 2) FIT2-TVP1c-F, TAAGAATAGAGTGTAAGGGTGGTAGTTGTTCC;
 (SEQ ID NO: 25)
 PGK-R-TVP, GCTTGGCTGGACGTAACTCCTCTTCAGACC.

[0080] The Neo cassette was then removed from BAC-NEO by treating cells with arabinose to induce the endogenous flip recombinase resulting in a single loxP and Frt site left behind in intron 1, and also sensitivity to kanamycin. This construct is called BAC-Frt-loxP.

[0081] Next, insertion of a second loxP site downstream of exon 2 was made by PCR amplification of pL451 with the following primers:

FIT2pL451b-F, (SEQ ID NO: 50)
 acaagcttagttggcagactctgctggcggtgccaccatgttgccagcag
 GATATCGAATTC;

-continued

FIT2pL451b-R,
 (SEQ ID NO: 51)
 acgatgaggcaggtgtctccctctgtgagcctcagctctccctctgg
 AGTGGATCCACC.

[0082] 200 ng of PCR product was electroporated into SW105 cells harboring BAC-Frt-loxP and cells were again selected for kanamycin resistance and the new recombined BAC was designated BAC-Frt-Loxp-exon2-NEO-loxP.

[0083] Homologous recombination was verified using the following primers:

(SEQ ID NO: 52)
 1) FIT2-TVPC-4R, agtgagttccagaacacgcaggctacacag;
 (SEQ ID NO: 27)
 BGH-F-TVP, GAACCAGCTGGGGCTCGACTAGAGCTTGCGG;
 (SEQ ID NO: 53)
 2) FIT2-TVPC5-F, gctcagcagaggagagcagcctgctgacgt;
 (SEQ ID NO: 25)
 PGK-R-TVP, GCTTGGCTGGACGTAACTCCTCTTCAGACC.

[0084] Following confirmation that exon 2 was flanked by both an upstream loxp-frt site and downstream loxp-neo cassette from pL451, a diphtheria toxin cassette with Amp resistance, DTA (kind gift of Chingwen Yang, Rockefeller University) was homologously recombined into BAC P22-NEO. 50 bp homology arms were added by PCR to the DTA cassette using the following pair of primers:

FIT2-DTA-F:
 (SEQ ID NO: 42)
 ACAGTCCCAGCTCCCATGGCACTCCTCACTGTAAATATAACTCGCCGATG
 gaacaactccgcgcgcgcgcgc;
 FIT2-DTA-R:
 (SEQ ID NO: 43)
 GCTGGCCTGGAACCTCACTTTATAGAGGGCTGGTTTGAACCTGTGTTG
 gagtaaaccttggtctgacag.

[0085] 200 ng of PCR product was electroporated into SW105 cells harboring the BAC-P22 Frt-Loxp-exon2-NEO-loxP and colonies were selected that were Chlor, Kan and Amp resistant. The completed vector is now designated BAC-P22 Frt-Loxp-exon2-NEO-loxP-DTA. Targeting of the DTA cassette was verified using the following two sets of PCR primer pairs:

(SEQ ID NO: 44)
 1) FIT2-TVPC5-F, CTTCGTGCACACTAGTCAAGCATCCTACCAAC;
 (SEQ ID NO: 33)
 POLIIP1R-TVP, CCGGAGCCACCTTCTCTCCAACGTCCTCCG;
 (SEQ ID NO: 45)
 2) FIT2-TVPC7-R, CTATTTTGAAACAGGATCTCTTACGTGACCC;
 (SEQ ID NO: 35)
 AMP1F-TVP, CTGAGATAGGTGCCTCACTGATTAAGCATTTG.

[0086] 10 µg of BAC-P22 Frt-Loxp-exon2-NEO-loxP-DTA was cut with NotI to linearize and then electroporated into ES cells at the Columbia University Transgenesis facility.

ES cells will be screened for homologous recombination by Southern blot analysis. ES cell DNA will be digested in 96 well plates with NcoI and probed with a 300 bp fragment which is the same fragment replaced by the DTA cassette on the BAC-P22 Frt-Loxp-exon2-NEO-loxP-DTA. Wild-type alleles yield a 2.8 kb fragment and Neo-floxed exon 2 allele will result in the appearance of a 5.6 kb fragment. Removal of the Neo cassette by crossing Neo-floxed mice with a flip-recombinase expressing mouse line (e.g. constitutive expression driven by the beta-actin promoter available for purchase from Jackson Laboratories, Bar Harbor Me.) will result in a floxed exon 2 allele (without the neo cassette downstream of exon 2) of 6 kb. Exon 2 can be deleted in a tissue- and stage-specific manner by crossing mice to cre or flip recombinase transgenic mice with the recombinase under the control of a tissue or developmentally regulated promoter. Many of these transgenic lines expressing cre or flip are available for purchase.

[0087] Regulated promoter for FIT1 and FIT2 expression. To generate an inducible expression system for murine FIT1 and FIT2, FIT1-V5 and FIT2-V5 (both having c-terminal V5 epitopes) have been subcloned from pcDNA3.1 topo directional (plasmid from Invitrogen corp.) using restriction enzymes HindIII and PmeI into pcDNA5/TO cut with restriction enzymes HindIII and EcoRV. pcDNA5/TO contains two tetracycline operator sites in the promoter region of the plasmid that serve as binding sites for the tetracycline repressor. Induction of either FIT1 or FIT2 expression will be achieved by treating cells with 1 µg/ml of tetracycline or doxycycline. All cell lines that will be used must express the tetracycline repressor. Tetracycline repressor expressing cells will be generated by stably transfecting cells with pcDNA6/TR (from Invitrogen corp.) and selecting for G418 resistance. pcDNA6/TR harboring cells will also be made to stably harbor FIT1 and FIT2 pcDNA5/TO constructs by selection on hygromycin.

Results and Discussion

[0088] Identification of FIT genes. The initial goal was to identify genes involved in intracellular fatty acid transport toward either storage in lipid droplets as triglyceride or catabolism via beta-oxidation in peroxisomes and mitochondria. Fenofibrate and other fibrate drugs are agonists for the peroxisome proliferator-activated receptor alpha (PPARalpha) nuclear hormone receptor, and activation of PPARalpha leads to the induction of the genes coding for proteins involved in the entire biochemical repertoire of beta-oxidation (17-19). To carry out this goal, genotype matched wild-type and PPARalpha deficient mice were fed a diet containing fenofibrate for 7 days. mRNA from livers were used to query gene arrays. Since most of the genes activated by PPARalpha likely have been identified, the focus was exclusively on genes that were listed as expression sequence tags (ESTs) or having unknown function. By performing BLAST searches against the mouse genome, many of the ESTs to the 3 prime end of the final exons of genes were located. This analysis was followed by both an examination using the Signal P algorithm to determine the putative cellular location of the gene product and using Novartis SymAtlas (<http://symatlas.gnf.org/SymAtlas/>) to determine the putative tissue expression pattern. Attention was directed toward a particular unknown transcript, named Fibrate Induced Transcript 1 (FIT1, Affymetrix number 1451488). FIT1 potentially has multiple transmembrane domains (FIG. 1D), was putatively located in the secre-

tory pathway (determined by Signal P), and highly expressed in heart and skeletal muscle by gene array studies (determined by Novartis Gene Atlas). However, FIT1 did not have homology to known proteins or known protein domains found in any species. These characteristics indicated a protein potentially involved in lipid transport in oxidative tissues.

[0089] Performing a BLAST search of the full-length mouse FIT1 amino acid sequence against the expressed data base, a second FIT1 homolog was identified in mammals that was designated FIT2. Mammals have two FIT genes, FIT1 and FIT2, while amphibians, birds, fish, insects, worms have a single FIT gene exhibiting higher homology to FIT2 (FIG. 5B) *S. cerevisiae* is an exception because it has two FIT2 orthologs. A second FIT2 ortholog not shown in the cladogram of FIG. 5A is called SCS3. FIT2 was found on the same Affymetrix gene array used to identify FIT1 (Affymetrix number 1454935) and was also increased by fenofibrate on the gene array. The expression of both mouse FIT1 and FIT2 were confirmed to be induced by fenofibrate in a PPAR α -dependent fashion in liver (FIG. 6). Northern blot analysis of mouse tissues indicated that FIT1 is highly expressed in heart and skeletal muscle, and to lower levels in liver, kidney, brown adipose, testes, and eye (FIG. 1A). Western blot analysis of mouse tissues indicated that FIT1 protein was detected primarily in heart and at low levels in liver and skeletal muscle (FIG. 1B). Mouse FIT2 mRNA was detected as two transcripts in most tissues examined with highest levels in heart, skeletal muscle and brown adipose tissue (FIG. 1A). Note that mFIT2 but not mFIT1 is expressed in white adipose tissue (FIG. 1A). Western blot analysis indicated FIT2 protein highest in heart, and lower levels in lung, liver, and kidney (FIG. 1B). An examination of human tissues showed that FIT1 was primarily expressed in heart and skeletal muscle, while FIT2 was expressed in all tissue represented on the Northern blot (FIG. 1C). Together, these analyses indicated that both mouse and human FIT 1 have a more restricted expression pattern to oxidative tissues, while FIT2 has a broader tissue expression pattern.

[0090] FIT1 and FIT2 are localized to the endoplasmic reticulum. In order to define a specific function to FIT proteins, both subcellular fractionation of mouse heart membranes and confocal immunolocalization studies were carried out. Sucrose density fractionation of mouse heart membranes indicated that both FIT1 and FIT2 were co-localized exclusively with endoplasmic reticulum (ER) membrane fractions (FIG. 2A). Expression of a c-terminal V5 tagged FIT1 and FIT2 in HEK 293 cells co-localized with the ER resident protein calnexin (FIG. 2B). Importantly, the V5 tag on FIT1 and FIT2 did not abolish its activity (FIG. 8). Together, the data indicated that FIT1 and FIT2 are localized in the ER.

[0091] Overexpression of FIT1 and FIT2 results in the formation of lipid droplets. In order to determine if FIT proteins play a role in lipid metabolism, experiments were designed to overexpress FIT proteins in cells. FIT1 and FIT2 were overexpressed in HEK293 cells and examined using the fluorescent lipid droplet stain BODIPY493/503. FIG. 3A shows that overexpression of FIT1 or FIT2 resulted in the accumulation of lipid droplets. FIT1 overexpression led to the accumulation of multiple droplets per cell with one or two larger droplets per cell, while FIT2 expressed to similar levels as FIT1 (FIG. 7) led to the frequent appearance of a single large droplet. Cells expressing DGAT1, one of two acyltransferases important in the committed step in TG biosynthesis (20) showed multiple lipid droplets smaller than those produced in FIT1

and FIT2 expressing cells (FIG. 3). Overexpression of FIT1 and FIT2 in HeLa cells resulted in similar findings except that FIT2 expression resulted in multiple large droplets per cell, together indicating that FIT1 and FIT2-induced lipid droplet accumulation is not cell-type specific (FIG. 9). Compared to mock transfected cells, cellular TG mass was significantly increased in cells expressing FIT1 and FIT2 (FIG. 3B). These data are consistent with the fluorescent images indicating the presence of lipid droplets in FIT1 and FIT2 expressing cells (FIG. 3A). As a positive control, cells were transfected with DGAT1 or DGAT2, a second acyltransferases important in the committed step in TG biosynthesis (20). Overexpression of DGAT1 or DGAT2 resulted in increased levels of cellular TG that were significantly greater than in FIT1 and FIT2 cells (FIG. 3A).

[0092] Human FIT expression produces lipid droplets. Overexpression of human FIT2 (hFIT2) and human FIT2 with a C-terminal V5 epitope tag (hFIT2-V5) in HEK293 cells resulted in numerous lipid droplets compared to mock transfected control cells (FIG. 17).

[0093] FIT proteins do not enhance triglyceride biosynthesis. It was also determined whether FIT1 and FIT2 enhance TG biosynthesis causing lipid droplets to form by quantifying the rate of TG biosynthesis using radiolabeled glycerol as a precursor for TG. Cells expressing FIT1 or FIT2 showed similar rates of TG biosynthesis compared to mock transfected cells, indicating that the accumulation of lipid droplets in FIT1 and FIT2 expressing cells is not the result of enhanced TG biosynthesis. The mRNAs of genes important in fatty acid and TG biosynthesis were not changed in cells expressing FIT1 or FIT2 (FIG. 10). As expected from previous studies, DGAT1 and DGAT2 overexpression led to a significant increase in TG biosynthetic rate (20) (21). To test if increased cellular TG is the result of partitioning of TG into lipid droplets, cells were incubated with ^{14}C glycerol tracer for 24 hrs and radiolabel in lipid droplets were quantified. FIG. 3C shows that cells expressing FIT1 and FIT2 had a significant increase in the percent of labeled glycerol in lipid droplets compared to mock transfected cells. As a positive control, DGAT1 and DGAT2 expressing cells exhibited a significant increase in radiolabeled glycerol in lipid droplets compared to mock, FIT1 and FIT2 expressing cells (FIG. 3C). Taken together, these results indicate that FIT1 and FIT2 do not directly mediate triglyceride biosynthesis, but lipid droplet formation leading to the accumulation of cellular neutral lipids.

[0094] shRNA suppression of FIT2 abolishes lipid droplet formation during adipogenesis. To provide a direct test if FIT proteins are essential for the formation of lipid droplets, knockdown of FIT expression was sought in established cellular models of lipid droplet formation. If FIT genes are essential for lipid droplet formation, then the NIH-3T3 L1 cell line, a classic adipocyte differentiation cell model that produces large amounts of lipid droplets during differentiation of pre-adipocytes into adipocytes, should express FIT genes during adipogenesis at the onset of lipid droplet accumulation. FIGS. 4B and 4C show that high levels of FIT2 at both mRNA and protein levels, but not FIT1 (data not shown), were detected during adipogenesis at the onset of formation of visible lipid droplets (FIG. 4A). This is in line with the observation that Fin and not FIT1 are expressed in white adipose tissue in vivo (FIGS. 1A,B). If FIT2 is indeed essential for droplet formation, then suppression of FIT2 expression should abolish lipid droplet formation. Pre-adipocytes

cells infected with lentivirus expressing shRNA against FIT2, a control shRNA, or no virus were induced to differentiate. FIT2 mRNA and protein were significantly suppressed in adipocytes infected with lentivirus expressing FIT2 shRNA. Examination of these cells for lipid droplets showed that cells having suppressed FIT2 expression had an almost complete absence of lipid droplets in pre-adipocytes (day 0) and in mature adipocytes (between day 4 and 9) (FIG. 4A). Only a low level of cells expressing the FIT2shRNA exhibited multiple lipid droplets per cell between day 6 and 9 (FIG. 4A). Further examination of FIT2 suppressed cells showed that the expression of PPARGgamma and AP2, genetic markers of adipocyte differentiation, were not changed (FIG. 4B). Triglyceride biosynthesis or triglyceride lipase activities were similar in adipocytes having a knockdown of FIT2 compared to controls (FIG. 11-11B). Taken together, the data indicate that knockdown of FIT2 specifically inhibited lipid droplet formation.

[0095] FIT is overexpressed in steatotic livers of ob/ob mice. Ob/ob mice are insulin resistant, have fatty livers and are obese. RNA was isolated from wild-type and ob/ob mouse livers and adipose tissue and analyzed by Northern blot (20 µg of RNA per lane). FIG. 12 shows results from two independent mice per genotype. FIG. 12 indicates that FIT1 is upregulated in both livers and adipose tissue of ob/ob mice compared to wild-type lean controls. This data suggests that FIT1 overexpression in livers of obese animals might be responsible for the formation of fatty liver.

[0096] FIT1 and FIT2 overexpression in mouse liver increases lipid deposition. Overexpression of mouse FIT1 and FIT2 in mouse liver causes triglyceride accumulation. Mouse FIT1 and FIT2 were first subcloned into adenovirus shuttle vector (pVW-CVM K-NpA) and adenovirus was synthesized (service provided by Viraquest, Iowa). Two groups of 6 wild-type male C57BL6J mice were injected intravenously with 1×10^8 pfu with empty adenovirus control (adEmpty) or adenovirus expression FIT1 (adFIT1). All mice were fed a standard chow diet for the first 3 days, then switched to a high fat diet (cat#TD.93075 Harlan Teklad) for 4 days. Perfused livers from mice were either frozen in OTC for producing frozen sections for oil-red-o staining, or fixed in 10% formalin and embedded in paraffin for H&E staining. FIG. 13A shows that control adenovirus injected mice had normal lipid deposition and liver morphology, while mice injected with the AdFIT1 and AdFIT2 adenovirus showed an accumulation of lipid in livers. FIG. 13B shows increased protein levels of FIT1 and FIT2 in mouse livers injected with FIT1 and FIT2 adenoviruses compared to control injected mice.

[0097] Rosiglitazone induces mFIT2 expression. NIH 3T3 preadipocytes were differentiated as in FIG. 14 for the days indicated (0, 1, 2, or 3 days) and treated or not treated with 1 µM rosiglitazone for 24 hrs. mRNA was isolated and analyzed by Northern blot analysis. FIT2 mRNA was increased at all time points of differentiation by treatment with rosiglitazone. Importantly, rosiglitazone increased FIT2 at time point zero indicating that the effect is likely independent of differentiation of the preadipocytes into adipocytes.

[0098] Lipid droplet formation in cells transfected with wild-type and mutant FIT2. The effects of mutations in amino acids comprising a highly conserved domain in mouse FIT2 were observed on lipid droplet formation. Amino acids 157 phenylalanine (F), 158 leucine (L), 159 leucine (L), 164 leucine (L), and 169 glutamic acid (E) are among the most highly

conserved amino acids found in all species having a FIT2 homolog. Mutations in the tandem amino acids FLL (amino acids 157 through 159) substituted with alanine (A) residues resulted in a FIT2 protein that produced more and brighter droplets than the wild-type FIT2 (FIT2-V5) transiently expressed in HEK 293 cells (FIG. 15). FIT2 mutants having either the 164L or 169E residue substituted by alanine resulted in a greatly diminished ability to produce droplets. Moreover, the L164A and E169A mutants both produced multiple small droplets, a phenotype distinct from the large droplets produced by wild-type and FLL157-9AAA mutant FIT2 proteins (FIG. 15). Importantly, the phenotypes observed were not due to changes in FIT2 protein levels, although L164A and E169A mutants had a minor decrease in levels as well as minor cleavage of the signal peptide as shown in Western blot FIG. 16. Together, the results indicate that the FLL domain plays a role to limit FIT2 activity, while the 164L and 169E residues are essential for FIT2 to form droplets. Thus, these amino acid domains on FIT2 can serve as targets for small molecule activators and inhibitors that may interact with these amino acid domains to either augment FIT2 activity or inhibit FIT2 activity.

[0099] Mouse transgenic models of FIT1 and FIT2 overexpression: liver-specific expression. Transgenic mice were generated that overexpress mouse FIT1 and FIT2 specifically in liver. Based on the finding that overexpression of FIT1 and FIT2 in mouse liver using adenovirus results in fatty liver on a high fat diet, these transgenic mouse models are expected to have fatty liver on high fat diets. These animal models should be suitable to study the progression of fatty liver diseases (alcoholic and non-alcoholic) and steatohepatitis as well as the role of fatty liver in type 2 diabetes and insulin resistance. In addition, these models will be useful in testing therapies for these diseases, such as screening therapeutic compounds (small molecules, proteins, RNAi, aptamers).

[0100] Mouse transgenic models of FIT1 and FIT2 overexpression: skeletal muscle-specific expression. Transgenic mice were generated that overexpress mouse FIT1 specifically in skeletal muscle. This animal model is expected to be useful in studying type 2 diabetes and obesity, and muscle metabolism and function. This model will be useful in testing therapies or screening therapeutic compounds (small molecules, proteins, RNAi, aptamers) for diseases (rhabdomyolysis, myositis, type 2 diabetes, lipotoxicity) as well as improving normal physiology (i.e. muscle function, lipid and glucose metabolism).

[0101] Mouse transgenic models of FIT1 and FIT2 overexpression: heart-specific expression. Transgenic mice were generated that overexpress mouse FIT1 specifically in cardiac myocytes. These mice are expected to be suitable models to study cardiomyopathy, and defects in cardiac function related to altered cardiac metabolism. This model will be useful in testing therapies or screening therapeutic compounds (small molecules, proteins, RNAi, aptamers) for diseases such as cardiomyopathy, cardiac dysfunction, cardiac ischemia, and altered cardiac metabolism, as well as improving normal physiology (i.e. cardiac function, lipid and glucose metabolism).

[0102] Mouse transgenic models of FIT1 and FIT2 overexpression: adipose-specific expression. Transgenic mice were generated that overexpress mouse FIT2 specifically in adipose tissue (white and brown adipose). These transgenic mice are expected to be useful as a model of obesity and type 2 diabetes and metabolic syndrome. These transgenic mice can

be used to test therapeutic compounds or other therapies to treat obesity, type 2 diabetes and metabolic syndrome.

[0103] Mouse deficiency models for FIT1 and FIT2: FIT1 gene targeted mice. FIT1 Knockout mice have been generated and found to be viable and fertile. These mice might be a suitable model for defects in cardiac, skeletal muscle, liver and kidney dysfunction and therefore are expected to also be useful to test therapeutic agents that regulate muscle, heart, liver, and kidney function.

[0104] Mouse deficiency models for FIT1 and FIT2: FIT2 gene targeted mice. The targeted A3 ES cell line was used to generate chimeric mice. It was determined that deletion of FIT2 results in embryonic lethality. Mouse embryonic fibroblasts from FIT2 knockouts may be useful as a model to screen for small molecule inhibitors of FIT genes. In addition, mice heterozygous for FIT2, which are viable, might be a suitable model to study the effects of inhibitors or activators of FIT2, as well as assessing the effects of having reduced levels of FIT2 on cardiac, muscle, liver, kidney and brain function. These mice having 50% less FIT2 might mimic humans that are heterozygous for mutations in FIT2, since homozygous mutations would be expected to be extremely rare.

[0105] FIT2 Conditional targeted mice. Based on the finding that gene targeted deletion of FIT2 results in embryonic lethality, BAC recombineering was used to produce a "floxed" allele of FIT2 to conditionally knock it out in adult mice. Conditional knockout mice for FIT2 are expected to be useful for studying organ specific effects of FIT2 inhibition on normal and pathophysiology. Conditional knockout mice will be an important model to test the safety and efficacy of inhibiting FIT2 in specific cell types and organs. For example, knockdown of FIT2 specifically in white adipose tissue should result in resistance to obesity and enhanced insulin sensitivity.

[0106] The present study describes for the first time the identification of a highly conserved family of proteins that are essential in mammalian cells for the formation of lipid droplets, independent of TG biosynthesis. FIT genes encode for multi-transmembrane, endoplasmic reticulum localized proteins. Overexpression of FITs in cell culture and mouse liver resulted in the formation of lipid droplets without enhancing triglyceride biosynthesis. Moreover, shRNA silencing of FIT genes in white adipocytes prevented lipid droplet formation during adipogenesis. Reagents that regulate FIT expression or activity are expected to impact the many diseases associated with excessive lipid droplet formation, such as obesity, diabetes, and atherosclerosis. Regulation of energy metabolism, feeding behavior and hepatic glucose output is highly regulated by lipids and energy status (ATP, AMP) in the brain. Inhibiting or activating FIT1 or FIT2 genes or protein activity in the brain (using small molecules, or nucleic acids, ASO,

RNAi, aptamers) may beneficially alter energy metabolism, feeding behavior and hepatic glucose output in humans.

REFERENCES

- [0107]** 1. S. Martin, R. G. Parton, *Nat Rev Mol Cell Biol* 7, 373 (May, 2006).
- [0108]** 2. R. Zechner, J. G. Strauss, G. Haemmerle, A. Lass, R. Zimmermann, *Curr Opin Lipidol* 16, 333 (June, 2005).
- [0109]** 3. J. E. Schaffer, *Curr Opin Lipidol* 14, 281 (June, 2003).
- [0110]** 4. B. B. Kahn, J. S. Flier, *J Clin Invest* 106, 473 (August, 2000).
- [0111]** 5. B. M. Spiegelman, J. S. Flier, *Cell* 104, 531 (Feb. 23, 2001).
- [0112]** 6. G. I. Shulman, *J Clin Invest* 106, 171 (July, 2000).
- [0113]** 7. H. Mullner, G. Daum, *Acta Biochim Pol* 51, 323 (2004).
- [0114]** 8. D. L. Brasaemle, G. Dolios, L. Shapiro, R. Wang, *J Biol Chem* 279, 46835 (Nov. 5, 2004).
- [0115]** 9. P. Liu et al., *J Biol Chem* 279, 3787 (Jan. 30, 2004).
- [0116]** 10. M. Beller et al., *Mol Cell Proteomics* (Mar. 16, 2006).
- [0117]** 11. C. Londos et al., *Ann N Y Acad Sci* 892, 155 (Nov. 18, 1999).
- [0118]** 12. C. Londos, D. L. Brasaemle, C. J. Schultz, J. P. Segrest, A. R. Kimmel, *Semin Cell Dev Biol* 10, 51 (February, 1999).
- [0119]** 13. A. B. Novikoff, P. M. Novikoff, O. M. Rosen, C. S. Rubin, *J Cell Biol* 87, 180 (October, 1980).
- [0120]** 14. E. J. Blanchette-Mackie et al., *J Lipid Res* 36, 1211 (June, 1995).
- [0121]** 15. K. Tauchi-Sato, S. Ozeki, T. Houjou, R. Taguchi, T. Fujimoto, *J Biol Chem* 277, 44507 (Nov. 15, 2002).
- [0122]** 16. A. Pol et al., *Mol Biol Cell* 15, 99 (January, 2004).
- [0123]** 17. D. J. Mangelsdorf et al., *Cell* 83, 835 (Dec. 15, 1995).
- [0124]** 18. B. Staels et al., *Circulation* 98, 2088 (Nov. 10, 1998).
- [0125]** 19. I. Issemann, S. Green, *Nature* 347, 645 (Oct. 18, 1990).
- [0126]** 20. S. Cases et al., *Proc Natl Acad Sci USA* 95, 13018 (Oct. 27, 1998).
- [0127]** 21. S. Cases et al., *J Biol Chem* 276, 38870 (Oct. 19, 2001).
- [0128]** 22. R. Ylitalo, O. Jaakkola, P. Lehtolainen, S. Yla-Herttuala, *Life Sci* 64, 1955 (1999).
- [0129]** 23. D. J. Rader, E. Pure, *Cell Metab* 1, 223 (April, 2005).
- [0130]** 24. A. K. Student, R. Y. Hsu, M. D. Lane, *J Biol Chem* 255, 4745 (May 25, 1980).
- [0131]** 25. S. J. Smith et al., *Nat Genet.* 25, 87 (May, 2000).
- [0132]** 26. Warming S, Costantino N, Court D L, Jenkins N A, Copeland N G. Simple and highly efficient BAC recombineering using galK selection. *Nucleic Acids Res.* 2005 Feb. 24; 33(4):e36.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 58

<210> SEQ ID NO 1

<211> LENGTH: 292

-continued

<212> TYPE: PRT
<213> ORGANISM: Human
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: FIT1

<400> SEQUENCE: 1

Met Glu Arg Gly Pro Val Val Gly Ala Gly Leu Gly Ala Gly Ala Arg
1 5 10 15
Ile Gln Ala Leu Leu Gly Cys Leu Leu Lys Val Leu Leu Trp Val Ala
20 25 30
Ser Ala Leu Leu Tyr Phe Gly Ser Glu Gln Ala Ala Arg Leu Leu Gly
35 40 45
Ser Pro Cys Leu Arg Arg Leu Tyr His Ala Trp Leu Ala Ala Val Val
50 55 60
Ile Phe Gly Pro Leu Leu Gln Phe His Val Asn Pro Arg Thr Ile Phe
65 70 75 80
Ala Ser His Gly Asn Phe Phe Asn Ile Lys Phe Val Asn Ser Ala Trp
85 90 95
Gly Trp Thr Cys Thr Phe Leu Gly Gly Phe Val Leu Leu Val Val Phe
100 105 110
Leu Ala Thr Arg Arg Val Ala Val Thr Ala Arg His Leu Ser Arg Leu
115 120 125
Val Val Gly Ala Ala Val Trp Arg Gly Ala Gly Arg Ala Phe Leu Leu
130 135 140
Ile Glu Asp Leu Thr Gly Ser Cys Phe Glu Pro Leu Pro Gln Gly Leu
145 150 155 160
Leu Leu His Glu Leu Pro Asp Arg Arg Ser Cys Leu Ala Ala Gly His
165 170 175
Gln Trp Arg Gly Tyr Thr Val Ser Ser His Thr Phe Leu Leu Thr Phe
180 185 190
Cys Cys Leu Leu Met Ala Glu Glu Ala Ala Val Phe Ala Lys Tyr Leu
195 200 205
Ala His Gly Leu Pro Ala Gly Ala Pro Leu Arg Leu Val Phe Leu Leu
210 215 220
Asn Val Leu Leu Leu Gly Leu Trp Asn Phe Leu Leu Leu Cys Thr Val
225 230 235 240
Ile Tyr Phe His Gln Tyr Thr His Lys Val Val Gly Ala Ala Val Gly
245 250 255
Thr Phe Ala Trp Tyr Leu Thr Tyr Gly Ser Trp Tyr His Gln Pro Trp
260 265 270
Ser Pro Gly Ser Pro Gly His Gly Leu Phe Pro Arg Pro His Ser Ser
275 280 285
Arg Lys His Asn
290

<210> SEQ ID NO 2
<211> LENGTH: 262
<212> TYPE: PRT
<213> ORGANISM: Human
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: FIT2

<400> SEQUENCE: 2

-continued

Met	Glu	His	Leu	Glu	Arg	Cys	Glu	Trp	Leu	Leu	Arg	Gly	Thr	Leu	Val	1	5	10	15
Arg	Ala	Ala	Val	Arg	Arg	Tyr	Leu	Pro	Trp	Ala	Leu	Val	Ala	Ser	Met	20	25	30	
Leu	Ala	Gly	Ser	Leu	Leu	Lys	Glu	Leu	Ser	Pro	Leu	Pro	Glu	Ser	Tyr	35	40	45	
Leu	Ser	Asn	Lys	Arg	Asn	Val	Leu	Asn	Val	Tyr	Phe	Val	Lys	Val	Ala	50	55	60	
Trp	Ala	Trp	Thr	Phe	Cys	Leu	Leu	Leu	Pro	Phe	Ile	Ala	Leu	Thr	Asn	65	70	75	80
Tyr	His	Leu	Thr	Gly	Lys	Ala	Gly	Leu	Val	Leu	Arg	Arg	Leu	Ser	Thr	85	90	95	
Leu	Leu	Val	Gly	Thr	Ala	Ile	Trp	Tyr	Ile	Cys	Thr	Ser	Ile	Phe	Ser	100	105	110	
Asn	Ile	Glu	His	Tyr	Thr	Gly	Ser	Cys	Tyr	Gln	Ser	Pro	Ala	Leu	Glu	115	120	125	
Gly	Val	Arg	Lys	Glu	His	Gln	Ser	Lys	Gln	Gln	Cys	His	Gln	Glu	Gly	130	135	140	
Gly	Phe	Trp	His	Gly	Phe	Asp	Ile	Ser	Gly	His	Ser	Phe	Leu	Leu	Thr	145	150	155	160
Phe	Cys	Ala	Leu	Met	Ile	Val	Glu	Glu	Met	Ser	Val	Leu	His	Glu	Val	165	170	175	
Lys	Thr	Asp	Arg	Ser	His	Cys	Leu	His	Thr	Ala	Ile	Thr	Thr	Leu	Val	180	185	190	
Val	Ala	Leu	Gly	Ile	Leu	Thr	Phe	Ile	Trp	Val	Leu	Met	Phe	Leu	Cys	195	200	205	
Thr	Ala	Val	Tyr	Phe	His	Asn	Leu	Ser	Gln	Lys	Val	Phe	Gly	Thr	Leu	210	215	220	
Phe	Gly	Leu	Leu	Ser	Trp	Tyr	Gly	Thr	Tyr	Gly	Phe	Trp	Tyr	Pro	Lys	225	230	235	240
Ala	Phe	Ser	Pro	Gly	Leu	Pro	Pro	Gln	Ser	Cys	Ser	Leu	Asn	Leu	Lys	245	250	255	
Gln	Asp	Ser	Tyr	Lys	Lys	260													

<210> SEQ ID NO 3

<211> LENGTH: 292

<212> TYPE: PRT

<213> ORGANISM: Mouse

<220> FEATURE:

<221> NAME/KEY: misc_feature

<223> OTHER INFORMATION: FIT1

<400> SEQUENCE: 3

Met	Glu	Arg	Gly	Pro	Thr	Val	Gly	Ala	Gly	Leu	Gly	Ala	Gly	Thr	Arg	1	5	10	15
Val	Arg	Ala	Leu	Leu	Gly	Cys	Leu	Val	Lys	Val	Leu	Leu	Trp	Val	Ala	20	25	30	
Ser	Ala	Leu	Leu	Tyr	Phe	Gly	Ser	Glu	Gln	Ala	Ala	Arg	Leu	Leu	Gly	35	40	45	
Ser	Pro	Cys	Leu	Arg	Arg	Leu	Tyr	His	Ala	Trp	Leu	Ala	Ala	Val	Val	50	55	60	
Ile	Phe	Gly	Pro	Leu	Leu	Gln	Phe	His	Val	Asn	Ser	Arg	Thr	Ile	Phe	65	70	75	80

-continued

Ala Ser His Gly Asn Phe Phe Asn Ile Lys Phe Val Asn Ser Ala Trp
85 90 95

Gly Trp Thr Cys Thr Phe Leu Gly Gly Phe Val Leu Leu Val Val Phe
100 105 110

Leu Ala Thr Arg Arg Val Ala Val Thr Ala Arg His Leu Ser Arg Leu
115 120 125

Val Val Gly Ala Ala Val Trp Arg Gly Ala Gly Arg Ala Phe Leu Leu
130 135 140

Ile Glu Asp Leu Thr Gly Ser Cys Phe Glu Pro Leu Pro Gln Gly Leu
145 150 155 160

Leu Leu His Glu Leu Pro Asp Arg Lys Ser Cys Leu Ala Ala Gly His
165 170 175

Gln Trp Arg Gly Tyr Thr Val Ser Ser His Thr Phe Leu Leu Thr Phe
180 185 190

Cys Cys Leu Leu Met Ala Glu Glu Ala Ala Val Phe Ala Lys Tyr Leu
195 200 205

Ala His Gly Leu Pro Ala Gly Ala Pro Leu Arg Leu Val Phe Leu Leu
210 215 220

Asn Val Leu Leu Leu Gly Leu Trp Asn Phe Leu Leu Leu Cys Thr Val
225 230 235 240

Ile Tyr Phe His Gln Tyr Thr His Lys Val Val Gly Ala Ala Val Gly
245 250 255

Thr Phe Ala Trp Tyr Leu Thr Tyr Gly Ser Trp Tyr His Gln Pro Trp
260 265 270

Ser Pro Gly Ile Pro Gly His Gly Leu Phe Pro Arg Ser Arg Ser Met
275 280 285

Arg Lys His Asn
290

<210> SEQ ID NO 4
<211> LENGTH: 262
<212> TYPE: PRT
<213> ORGANISM: Mouse
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: FIT2

<400> SEQUENCE: 4

Met Glu His Leu Glu Arg Cys Ala Trp Phe Leu Arg Gly Thr Leu Val
1 5 10 15

Arg Ala Thr Val Arg Arg His Leu Pro Trp Ala Leu Val Ala Ala Met
20 25 30

Leu Ala Gly Ser Val Val Lys Glu Leu Ser Pro Leu Pro Glu Ser Tyr
35 40 45

Leu Ser Asn Lys Arg Asn Val Leu Asn Val Tyr Phe Val Lys Leu Ala
50 55 60

Trp Ala Trp Thr Val Cys Leu Leu Leu Pro Phe Ile Ala Leu Thr Asn
65 70 75 80

Tyr His Leu Thr Gly Lys Thr Ser Leu Val Leu Arg Arg Leu Ser Thr
85 90 95

Leu Leu Val Gly Thr Ala Ile Trp Tyr Ile Cys Thr Ala Leu Phe Ser
100 105 110

Asn Ile Glu His Tyr Thr Gly Ser Cys Tyr Gln Ser Pro Ala Leu Glu

-continued

115	120	125
Gly Ile Arg Gln Glu His Arg Ser Lys Gln Gln Cys His Arg Glu Gly		
130	135	140
Gly Phe Trp His Gly Phe Asp Ile Ser Gly His Ser Phe Leu Leu Thr		
145	150	155
Phe Cys Ala Leu Met Ile Val Glu Glu Met Ala Val Leu His Glu Val		
165	170	175
Lys Thr Asp Arg Gly His His Leu His Ala Ala Ile Thr Thr Leu Val		
180	185	190
Val Ala Leu Gly Phe Leu Thr Phe Ile Trp Val Trp Met Phe Leu Cys		
195	200	205
Thr Ala Val Tyr Phe His Asp Leu Thr Gln Lys Val Phe Gly Thr Met		
210	215	220
Phe Gly Leu Leu Gly Trp Tyr Gly Thr Tyr Gly Tyr Trp Tyr Leu Lys		
225	230	235
Ser Phe Ser Pro Gly Leu Pro Pro Gln Ser Cys Ser Leu Thr Leu Lys		
245	250	255
Arg Asp Thr Tyr Lys Lys		
260		

<210> SEQ ID NO 5

<211> LENGTH: 274

<212> TYPE: PRT

<213> ORGANISM: *S. cerevisiae*

<220> FEATURE:

<221> NAME/KEY: misc_feature

<223> OTHER INFORMATION: YDR319 FIT

<400> SEQUENCE: 5

Met Ile Arg Gln Leu Asn Tyr Trp Ser Arg Lys Ala Tyr Leu Ile Tyr		
1	5	10
Pro Phe Gln Val Phe Val Gly Ala Leu Leu Ser Ile Val Val Ser Ser		
20	25	30
Glu Thr Leu Asn His Gln Lys Glu Thr Cys Ala Leu Leu Lys Ser Ser		
35	40	45
Asn Ile Phe Asn Val Ile Phe Ala Tyr Lys Ala Asn Gln Leu Trp Pro		
50	55	60
Phe Leu Phe Phe Ser Leu Ala Phe Leu Gln Ile Tyr Phe His Tyr Leu		
65	70	75
Ala Arg Met Asp Ile Leu Pro Leu Pro Ile Ser Ser Thr Glu Thr Ser		
85	90	95
Ser Ser Tyr Leu Thr Tyr Thr Asn His Trp Pro Leu Leu Lys Asn Arg		
100	105	110
Ile Ile Ser Ile Met Ile Thr Gln Tyr Ala Cys Lys Phe Val Leu Lys		
115	120	125
Tyr Leu Leu Leu Phe Leu Asn Phe Gln Phe Ile Asp His Val Phe Ile		
130	135	140
Trp Thr Gly Gly Glu Cys Ser Ser Gly Ser Lys Thr Thr Ser Ala Glu		
145	150	155
Lys Cys Arg Leu Glu Asn Gly Lys Trp Asp Gly Gly Phe Asp Ile Ser		
165	170	175
Gly His Phe Cys Phe Leu Val Ser Ile Ser Met Ile Leu Trp Met Glu		
180	185	190

-continued

Leu His Leu Phe Ser Arg Phe Val Gln Ala Glu Asp Met Phe Trp Val
 195 200 205
 Val Asn Lys Trp Val Arg Ala Cys Leu Ala Ile Val Cys Ala Val Leu
 210 215 220
 Val Ile Trp Ile Cys Ile Leu Trp Val Thr Ala Ile Tyr Tyr His Thr
 225 230 235 240
 Ile Leu Glu Lys Val Leu Gly Cys Leu Met Gly Phe Ile Cys Pro Val
 245 250 255
 Phe Ile Tyr His Ile Leu Pro Lys Ile Gly Ile Leu His Asn Tyr Leu
 260 265 270
 Tyr Leu

<210> SEQ ID NO 6
 <211> LENGTH: 380
 <212> TYPE: PRT
 <213> ORGANISM: *S. cerevisiae*
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: SCS3 FIT

<400> SEQUENCE: 6

Met Ser Ser Lys Trp Phe Asn Ala Ile His Leu Leu Val Cys Pro Leu
 1 5 10 15
 Thr Val Leu Val Gly Tyr Leu Met Asn Ala Tyr Gly Tyr Gly Ala Ala
 20 25 30
 Leu Gln Ala Thr Leu Asn Lys Asp Gly Leu Val Asn Ala Met Leu Val
 35 40 45
 Lys Lys Gly Trp Phe Trp Thr Ser Leu Val Gly Trp Trp Cys Ile Ile
 50 55 60
 Arg Tyr Arg Ala Val Pro Gly Ala Thr Gly Arg Asp Arg Arg His Ile
 65 70 75 80
 Val Gln Ser Phe Lys Arg Tyr Ala Ile Leu Thr Val Trp Trp Tyr Val
 85 90 95
 Phe Thr Gln Gly Ile Trp Phe Gly Val Gly Pro Ile Met Asp Leu Val
 100 105 110
 Phe Val Tyr Thr Gly Gly His Cys His Tyr Asp Val Phe Asp Asp Ala
 115 120 125
 Gly His Val Asn Glu Asp Phe Gln Gly Ser Val Thr Arg Thr Asn Arg
 130 135 140
 Ala Leu Ala Leu Ile His Asn Val Leu Thr Leu His Gly His His Gln
 145 150 155 160
 Glu His Arg Gln Gln Gln Leu Trp Asp Arg Ser Ile Gly Ser Ile Gln
 165 170 175
 Gly Ala Leu Gln Ala Thr Gln Pro Lys Thr Pro Lys Asn Val Thr Ala
 180 185 190
 Ser Ala Ala Ala Ala Ile Asn Thr Phe Ile His Asp Gln Met His Arg
 195 200 205
 Trp Gln Gly Pro Leu Thr Thr Ser Ala Gln Cys Arg Arg Phe Gly Gly
 210 215 220
 His Trp Ala Gly Gly His Asp Pro Ser Gly His Val Phe Leu Ala Thr
 225 230 235 240
 Leu Met Cys Met Phe Leu Leu Gly Glu Leu Arg Val Phe Gly Arg Arg
 245 250 255

-continued

Ala	Leu	Ala	His	Leu	Tyr	Ala	Gln	Lys	Trp	Gln	Leu	Val	Arg	Leu	Val
			260					265					270		
Thr	Arg	Leu	Phe	Asp	Thr	Gly	Pro	Leu	Trp	Thr	Trp	Arg	Arg	Cys	Gly
		275					280					285			
Gly	Gly	Ser	Met	Thr	Cys	Gly	Ala	Arg	Leu	Trp	Arg	Ala	Ile	Val	Glu
	290					295					300				
Pro	Pro	Val	Thr	Cys	Ala	Ala	Ala	Leu	Leu	Arg	Leu	Thr	Arg	Cys	Ile
305				310						315					320
Ala	Cys	Asp	His	Pro	Val	Ile	Ile	Leu	Leu	Thr	Leu	Leu	Val	Thr	Trp
			325						330					335	
Leu	Trp	Gln	Leu	Leu	Leu	Thr	Ala	Val	Ala	Ser	Arg	Phe	His	Thr	Val
		340						345					350		
Arg	Glu	His	Met	Ser	Gly	Leu	Leu	Ala	Ala	Tyr	Ile	Val	Thr	Gly	Leu
	355					360						365			
Val	Tyr	Ala	Arg	Asp	Ala	Ala	Ala	Leu	Arg	Pro	Val				
	370				375					380					

<210> SEQ ID NO 7
 <211> LENGTH: 283
 <212> TYPE: PRT
 <213> ORGANISM: C.elegans
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: FIT

<400> SEQUENCE: 7

Met	Ser	Thr	Arg	Arg	Ser	Ser	Thr	Arg	Ala	Asp	Ser	Thr	Thr	Lys	Arg
1				5					10					15	
Pro	Ala	Ser	Pro	Asn	Ser	Thr	Pro	Asn	Ala	Ala	Leu	Gly	Ile	Phe	Val
		20						25					30		
Ala	Ile	Ala	Arg	Gln	Ile	Leu	Phe	Ile	Asp	Ala	Arg	Lys	Val	Ala	Leu
	35				40							45			
Phe	Tyr	Leu	Ala	Phe	Val	Thr	Val	Leu	Ser	Phe	Ile	Glu	Ser	Arg	Ile
	50				55					60					
Glu	Leu	Asp	Ser	Thr	Tyr	Tyr	Leu	Val	Gln	Lys	His	Ser	Val	Leu	Asn
65			70						75					80	
Gln	Tyr	Gly	Val	Lys	Met	Gly	Trp	Phe	Trp	Thr	Leu	Val	Ile	Val	Gly
			85					90						95	
Pro	Phe	Ile	Trp	Phe	Ser	Ser	Lys	Ala	His	Asn	Arg	Arg	Asp	Arg	Asp
		100						105					110		
Gln	Pro	Ile	Val	Asp	Val	Cys	Arg	Leu	Gly	Val	Gly	Thr	Ala	Cys	Trp
	115					120						125			
Tyr	Phe	Ser	Val	Gln	Phe	Phe	His	Lys	Val	Leu	Ala	Leu	Thr	Ser	Met
	130				135						140				
Cys	Asp	Lys	Gly	Arg	Thr	Leu	Thr	Arg	Ala	Gln	Cys	Ser	Glu	Lys	Glu
145				150					155					160	
Gly	Val	Trp	Thr	Pro	Gly	Tyr	Asp	Ile	Ser	Gly	His	Cys	Phe	Leu	Met
		165						170						175	
Ile	Tyr	Ser	Ile	Leu	Ile	Ile	Thr	Glu	Glu	Ala	Ile	Ala	Tyr	Arg	His
	180							185					190		
Tyr	Gln	Gln	Val	Thr	Asp	Ala	Val	His	Gln	Met	Asp	Gly	Asp	Arg	Glu
	195					200						205			
Glu	His	Asp	Arg	Leu	Thr	Arg	Cys	Ile	Gln	Tyr	Phe	Phe	Val	Ala	Met
	210					215						220			

-continued

```

Leu Phe Leu His Ala Phe Trp Phe Lys Gln Ile Ile Ile Ser Val Leu
225                230                235                240

Tyr Tyr His Ile Phe Ile Glu Glu Ile Leu Gly Ala Val Ala Ala Val
                245                250                255

Val Cys Trp Phe Val Thr Tyr Arg Met Leu Tyr Pro Ala Gly Phe Leu
                260                265                270

Ala Ser Pro Ile Arg Arg Thr Val Gly Arg Lys
                275                280

```

```

<210> SEQ ID NO 8
<211> LENGTH: 423
<212> TYPE: PRT
<213> ORGANISM: D.melanogaster
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: FIT

```

```

<400> SEQUENCE: 8

```

```

Met Ala Thr Lys Arg Arg Pro Leu Arg Pro Asn Leu Gly Gly Thr Ala
1      5      10      15

Gly Ser Pro Ser Ser Ser Gly Ser Asn Met Asn Phe Arg Pro Gly Gly
                20      25      30

Pro Asp Ile Thr Arg Ser Glu Ala Arg Gly Thr Arg Pro Thr Ala Ala
                35      40      45

Pro Thr Ser Ile Arg Glu Ile Leu Val Met Gly Val Ile His Leu Cys
                50      55      60

Lys Lys Thr Ile Phe Phe Asn Thr Asp Leu Lys Val Ala Leu Tyr Leu
65      70      75      80

Gly Ser Leu Phe Val Ile Ser Val Ile Gly Asp Phe Val Pro Phe Pro
                85      90      95

Lys Thr Tyr Phe Ala Arg Ser Asp Asn Leu Phe Asn Gln Tyr Phe Val
                100     105     110

Lys Ile Gly Trp Gly Trp Thr Leu Leu Phe Val Val Pro Phe Leu Val
                115     120     125

Leu Ser Ala Tyr Thr Ile Thr Cys Gly Asp His Lys Arg Met Leu Arg
130     135     140

His His Phe Pro Arg Ile Val Ile Ala Thr Phe Phe Trp Phe Phe Trp
145     150     155     160

Thr Lys Leu Phe Asn Val Val Glu Asn Ser Tyr Gly Arg Cys Thr Thr
                165     170     175

Lys Gly Tyr Ala Thr Lys Ser Ser Cys Leu Lys Ala Gly His Leu Trp
                180     185     190

Lys Gly Phe Asp Ile Ser Gly His Ala Phe Ile Leu Ile His Ser Ser
195     200     205

Leu Val Leu Ile Glu Glu Ala Arg Pro Ile Ile Arg Trp Glu Thr Ile
210     215     220

Lys Glu His Ile Arg Asn Glu Arg His Asn Arg Ser Thr Ala Glu Asn
225     230     235     240

Ser Gly Thr Asn Pro Leu Arg Thr Leu Asn Glu Glu Gln Met Arg Ser
                245     250     255

Leu Gln Phe Leu Tyr Lys Arg Leu Thr Pro Ile Ile Arg Thr Leu Phe
260     265     270

Ile Gly Met Ala Ala Leu Gln Leu Leu Trp Asp Ile Met Leu Val Gly

```

-continued

275	280	285
Thr Met Leu Tyr Tyr His Arg Met Ile Glu Lys Val Ile Ser Gly Ile		
290	295	300
Ile Ala Ile Leu Thr Trp Tyr Phe Thr Tyr Arg Phe Trp Tyr Pro Thr		
305	310	315
Pro Gly Leu Leu Pro Glu Ala Pro Gly Asn Gly Ser Phe Ser Tyr Gln		
325	330	335
Arg Glu Ile Pro Thr Phe Pro Phe Lys Arg Pro Ser His Leu Ser Thr		
340	345	350
Gly Ala Ala Thr Thr Ser Ser Gly Ser Asn Ser Ser Arg Thr Asn Leu		
355	360	365
Asn Gly Lys Ala Ala Thr Thr Gly Val Pro Arg Asp Gln Gln Ile Pro		
370	375	380
Thr Phe Met Gly Met Pro Leu Phe Thr Ser Pro Lys Ala Ala Ser Ala		
385	390	395
Ala Ala Asn Leu Leu Met Ser Asp Gln Gln Lys Arg Glu Arg Asp Arg		
405	410	415
Glu Gln Gln Thr Leu Glu Ser		
420		

<210> SEQ ID NO 9
 <211> LENGTH: 242
 <212> TYPE: PRT
 <213> ORGANISM: A.gambiae
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: FIT

<400> SEQUENCE: 9

Met Ala Ser Lys Arg Lys Pro Ile His Thr Pro Ser Ala Ala Gly Ala		
1	5	10
Ala Gly Gly Asn Ala Ala Arg Pro Gln Met Asn Phe Arg Gln Gly Leu		
20	25	30
Asn Asp Thr Thr Ala Arg Ala Glu Ala Lys Gly Thr Arg Pro Thr Ala		
35	40	45
Thr Pro Thr Ser Ile Arg Glu Val Leu Thr Met Met Val Leu His Val		
50	55	60
Cys Lys Lys Ile Ile Phe Phe Asp Thr Ser Leu Lys Val Pro Leu Tyr		
65	70	75
Leu Gly Ser Leu Phe Ile Val Ser Leu Ile Gly Asp Phe Leu Pro Tyr		
85	90	95
Pro Lys Thr Tyr Leu Ala Arg Thr Asp Asn Leu Phe Asn Val Tyr Phe		
100	105	110
Val Lys Leu Gly Trp Ala Trp Thr Leu Leu Phe Ala Phe Pro Tyr Leu		
115	120	125
Ala Met Thr Ser Ile Thr Ile Cys Cys Gly Asp Asn Gln Arg Leu Ile		
130	135	140
Arg Asn His Leu Pro Arg Leu Gly Ile Ala Thr Val Phe Trp Phe Val		
145	150	155
Trp Thr Lys Leu Phe Asn Val Ile Glu Ser Ser Tyr Gly Arg Cys Ser		
165	170	175
Val Arg Gly Phe Asp Ala Lys Thr Pro Cys Leu Lys Ala Gly His Leu		
180	185	190

-continued

[illegible]

```
<210> SEQ ID NO 10
<211> LENGTH: 288
<212> TYPE: PRT
<213> ORGANISM: T.nigroviridis
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: FIT
```

<400> SEQUENCE: 10

Arg 1	Val	Thr	Ala	Ala	Leu	Arg	Ala	Ala	Ala	Arg	Arg	Phe	Leu	Gly	Leu
5				10				15							
Leu	Asn	Ala	Ala	Leu	Val	Leu	Ala	Ser	Asp	Leu	Leu	Ala	Arg	Leu	Phe
20				25				30							
Gly	Ser	Gly	Pro	Val	Arg	Arg	His	Phe	His	Leu	Leu	Leu	Ser	Ser	Leu
35				40				45							
Val	Leu	Leu	Gly	Pro	Ala	Leu	Ser	Phe	Trp	Val	Ser	Lys	Tyr	Ser	Ile
50				55				60							
Phe	Ala	Asn	Ser	His	Asn	Tyr	Leu	Tyr	Arg	Lys	Phe	Leu	Gly	Ser	Thr
65				70				75				80			
Trp	Gly	Trp	Thr	Cys	Thr	Leu	Thr	Gly	Ser	Phe	Val	Leu	Leu	Leu	Ser
85				90				95							
Ile	Ser	Ala	Arg	Arg	Ser	Ala	Ser	Thr	Ser	Leu	Lys	His	Leu	Ser	Arg
100				105				110							
Leu	Val	Val	Leu	Gly	Leu	Leu	Trp	Gly	Gly	Cys	Arg	Cys	Leu	Leu	Thr
115				120				125							
Leu	Leu	Glu	Asp	Ala	Ala	Gly	Ala	Cys	Tyr	Glu	Pro	Leu	Ser	Ser	Gly
130				135				140							
Pro	Glu	Ser	Glu	Gly	Leu	Ala	Ser	Pro	Leu	Gln	Pro	Leu	Leu	Leu	Leu
145				150				155				160			
His	Glu	Asp	Gln	Ser	Lys	Ala	Ser	Cys	Leu	Lys	Ala	Gly	Leu	Leu	Trp
165				170				175							
Arg	Gly	Tyr	Gln	Val	Ser	Gln	Glu	Val	Leu	Val	Leu	Cys	Leu	Cys	Cys
180				185				190							
Leu	Ala	Leu	Val	Glu	Glu	Val	Ser	Val	Phe	Arg	Phe	His	Leu	Asp	Gln
195				200				205							
Ala	Ala	Ser	Leu	His	Arg	Pro	Pro	Ile	Gly	Pro	Leu	Arg	Cys	Leu	Phe
210				215				220							
Leu	Leu	Cys	Val	Leu	Leu	Leu	Gly	Leu	Trp	Val	Phe	Leu	Leu	Leu	Cys
225				230				235				240			
Leu	Leu	Ala	His	Phe	Pro	Gln	Phe	Pro	Ser	Gln	Gln	Leu	Gly	Gly	Ala
245				250				255							
Val	Gly	Tyr	Leu	Gly	Trp	Arg	Gly	Leu	Tyr	Gln	Gly	Trp	Phe	Arg	Leu
260				265				270							
Pro	Pro	Ser	Trp	Met	Cys	Pro	Gly	Leu	Pro	Gly	Glu	Gly	Leu	Leu	Pro
275				280				285							

-continued

```

<210> SEQ ID NO 11
<211> LENGTH: 290
<212> TYPE: PRT
<213> ORGANISM: D.rerio
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: FIT

<400> SEQUENCE: 11

Met Phe Leu Asn Ser Ile Leu Val Val Ile Thr Asp Leu Ala Ala Gly
1      5      10      15
Leu Leu Gly Asn Thr Ser Phe Arg Arg His Phe His Leu Leu Leu Ser
20      25      30
Ala Leu Leu Leu Phe Gly Pro Leu Leu Ser Leu Trp Val Ser His Tyr
35      40      45
Ser Val Phe Ala Lys Arg Thr His Phe Leu Tyr Arg Val Phe Leu Arg
50      55      60
Ser Gly Trp Gly Trp Thr Cys Ile Phe Val Gly Ser Phe Val Phe Val
65      70      75      80
Leu Ser Phe Ser Val Arg Arg Ser Leu Thr Leu Ser Leu Arg His Leu
85      90      95
Ser Arg Leu Ala Val Ala Gly Gly Leu Trp Leu Gly Phe Arg Lys Leu
100     105     110
Leu Cys Leu Leu Glu Asn Ala Thr Gly Ser Cys Tyr Glu Pro Leu Ser
115     120     125
Ala Ala Leu Glu Met Thr Ser Gly Thr Asn Gly Glu Gly Gln Pro Leu
130     135     140
Leu Leu Leu Arg Glu Ala Glu Thr Lys Glu Thr Cys Val Arg Ser Gly
145     150     155     160
Met Leu Trp Arg Gly Tyr Glu Val Ser Glu Asp Ala Leu Leu Leu Cys
165     170     175
Leu Cys Cys Leu Leu Leu Ala Glu Glu Thr Ala Val Phe Gly Pro Tyr
180     185     190
Leu Asn Leu Gly Gly Pro Ser Glu Ala Pro Leu Arg Ile Leu Phe Leu
195     200     205
Phe Cys Val Leu Leu Leu Ser Leu Trp Val Phe Leu Leu Leu Cys Leu
210     215     220
Leu Ala Tyr Phe Pro Glu Phe Pro Thr Gln Leu Leu Gly Gly Ala Leu
225     230     235     240
Gly Cys Leu Ser Trp Arg Ala Leu Tyr Gln Gly Trp Tyr Arg Leu Arg
245     250     255
Pro Ser Trp Tyr Cys Pro Gly Arg Pro Gly Val Gly Leu Leu Ser Thr
260     265     270
Gln Ser Lys Gln Asp Glu Leu Leu Glu Thr Gln Thr Asn Ala Lys Glu
275     280     285

Ile Asp
290

```

```

<210> SEQ ID NO 12
<211> LENGTH: 260
<212> TYPE: PRT
<213> ORGANISM: X.laevis
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: FIT

```

-continued

<400> SEQUENCE: 12

```

Met Glu Arg Leu Glu Asn Cys Ala Gln Met Phe Gln Arg Lys Phe Leu
1           5           10           15
Asn Glu Ala Phe Arg Arg His Cys Pro Val Leu Leu Ala Cys Ile Ala
          20           25           30
Leu Gly Gly Ser Leu Leu Lys Glu Leu Ser Pro Leu Pro Asp Ser Tyr
          35           40           45
Trp Asn Asn Lys Arg Asn Val Leu Asn Val Tyr Phe Val Lys Phe Cys
          50           55           60
Trp Gly Trp Thr Leu Trp Leu Leu Leu Pro Phe Ile Thr Leu Thr Asn
65           70           75           80
Tyr Lys Leu Thr Gly Ser Ile Thr Lys Val Leu Arg Arg Leu Ser Ser
          85           90           95
Leu Leu Val Gly Thr Leu Phe Trp Tyr Leu Cys Thr Asn Leu Phe Leu
          100          105          110
Tyr Ile Glu His Ile Thr Gly Ser Cys Tyr Glu Ser Glu Ala Leu Leu
          115          120          125
Asp Ser Ile Glu His Gln Asp Arg Lys Glu Cys Arg Leu His Gly Gly
          130          135          140
Phe Trp His Gly Phe Asp Ile Ser Gly His Cys Phe Leu Leu Ser Tyr
          145          150          155          160
Cys Ile Leu Ile Ile Leu Glu Glu Thr Ser Val Ile Arg Ser Ile Gln
          165          170          175
Phe Glu Arg His Trp His Arg Met Ala Ile Asn Ala Gln Phe Thr Ala
          180          185          190
Leu Ser Ile Leu Val Ile Ile Trp Val Trp Met Phe Leu Cys Thr Ala
          195          200          205
Val Tyr Phe His Asn Ile Phe Gln Lys Val Ile Gly Thr Ala Phe Gly
          210          215          220
Met Leu Ala Trp Tyr Ile Thr Tyr Arg Trp Trp Tyr Leu Gln Pro Ile
          225          230          235          240
Ser Pro Gly Leu Pro Pro Ala Ser Ala Ser His Ser Glu Lys Glu Pro
          245          250          255
Val Tyr Lys Asn
          260

```

<210> SEQ ID NO 13

<211> LENGTH: 271

<212> TYPE: PRT

<213> ORGANISM: G.gallus

<220> FEATURE:

<221> NAME/KEY: misc_feature

<223> OTHER INFORMATION: FIT

<400> SEQUENCE: 13

```

Met Glu Arg Leu Glu Arg Cys Ala Arg Cys Leu Arg Ala Arg Leu Val
1           5           10           15
Ala Ala Ala Val Arg Arg Arg Leu Pro Trp Leu Leu Leu Gly Leu Val
          20           25           30
Phe Leu Gly Ser Ala Leu Lys Asp Gly Asp Leu Val Pro Glu Thr Pro
          35           40           45
Met Gln Asn Lys Arg Asn Val Phe Asn Val Tyr Phe Val Lys Val Ala
          50           55           60

```

-continued

Trp Ala Trp Thr Phe Trp Leu Leu Leu Pro Phe Ile Gly Val Thr Thr
 65 70 75 80
 Tyr Leu Phe Ala Lys Ser Lys Phe Leu Tyr Gly Pro Thr Lys Ser Ile
 85 90 95
 Leu Ala Ala Leu Arg Arg Leu Ser Thr Leu Leu Val Gly Thr Ala Val
 100 105 110
 Trp Tyr Val Cys Thr Glu Leu Phe Met Tyr Ile Glu Asn Leu Thr Gly
 115 120 125
 Thr Cys Ser Thr Ser Ser Lys Leu Ser Glu Pro His Gln Leu Tyr Ala
 130 135 140
 Thr Lys Gln Glu Cys His Arg Asn Asn Gly Ile Trp Asn Gly Phe Asp
 145 150 155 160
 Ile Ser Gly His Cys Phe Leu Leu Ser Tyr Cys Ala Leu Met Ile Val
 165 170 175
 Glu Glu Met Ala Val Leu Glu Gly Leu Ser Ile Asp Arg Asn Ser Arg
 180 185 190
 Leu Arg Val Val Ile Asn Gly Leu Phe Val Ser Leu Cys Phe Leu Thr
 195 200 205
 Met Ile Trp Val Phe Met Phe Leu Cys Thr Thr Val Tyr Phe His Asp
 210 215 220
 Phe Ser Gln Lys Leu Leu Gly Ala Leu Ile Gly Leu Ala Ala Trp Tyr
 225 230 235 240
 Ala Thr Tyr Arg Val Trp Tyr Leu Lys Pro Phe Ser Pro Gly Leu Pro
 245 250 255
 Leu Pro Asn Ile Pro Leu Ser Ser Lys Lys Tyr Ser Tyr Ser Arg
 260 265 270

<210> SEQ ID NO 14
 <211> LENGTH: 262
 <212> TYPE: PRT
 <213> ORGANISM: P.troglodytes
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: FIT2

<400> SEQUENCE: 14

Met Glu His Leu Glu Arg Cys Glu Trp Leu Leu Arg Gly Thr Leu Val
 1 5 10 15
 Arg Ala Ala Val Arg Arg Tyr Leu Pro Trp Ala Leu Val Ala Ser Met
 20 25 30
 Leu Ala Gly Ser Leu Leu Lys Glu Leu Ser Pro Leu Pro Glu Ser Tyr
 35 40 45
 Leu Ser Asn Lys Arg Asn Val Leu Asn Val Tyr Phe Val Lys Val Ala
 50 55 60
 Trp Ala Trp Thr Phe Cys Leu Leu Leu Pro Phe Ile Ala Leu Thr Asn
 65 70 75 80
 Tyr His Leu Thr Gly Lys Ala Gly Leu Val Leu Arg Arg Leu Ser Thr
 85 90 95
 Leu Leu Val Gly Thr Ala Ile Trp Tyr Ile Cys Thr Ser Ile Phe Ser
 100 105 110
 Asn Ile Glu His Tyr Thr Gly Ser Cys Tyr Gln Ser Pro Ala Leu Glu
 115 120 125
 Gly Val Arg Lys Glu His Gln Ser Lys Gln Gln Cys His Gln Glu Gly

-continued

130	135	140
Gly Phe Trp His Gly Phe Asp Ile Ser Gly His Ser Phe Leu Leu Thr		
145	150	155 160
Phe Cys Ala Leu Met Ile Val Glu Glu Met Ser Val Leu His Glu Val		
	165	170 175
Lys Thr Asp Arg Ser His Cys Leu His Thr Ala Ile Thr Thr Leu Val		
	180	185 190
Val Ala Leu Gly Ile Leu Thr Phe Ile Trp Val Leu Met Phe Leu Cys		
	195	200 205
Thr Ala Val Tyr Phe His Asn Leu Ser Gln Lys Val Phe Gly Thr Leu		
	210	215 220
Phe Gly Leu Leu Ser Trp Tyr Gly Thr Tyr Gly Phe Trp Tyr Pro Lys		
	225	230 235 240
Ala Phe Ser Pro Gly Leu Pro Pro Gln Ser Cys Ser Leu Asn Leu Lys		
	245	250 255
Gln Asp Ser Tyr Lys Lys		
	260	

<210> SEQ ID NO 15
 <211> LENGTH: 262
 <212> TYPE: PRT
 <213> ORGANISM: C.familiaris
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: FIT2

<400> SEQUENCE: 15

Met Glu His Leu Glu Arg Cys Ala Arg Leu Leu Arg Gly Thr Leu Val		
1	5	10 15
Arg Ala Ala Val Arg Arg Tyr Leu Pro Trp Ala Leu Ala Phe Ser Met		
	20	25 30
Leu Ala Gly Ser Val Leu Lys Glu Leu Ser Pro Leu Pro Glu Ser Tyr		
	35	40 45
Leu Ser Asn Lys Arg Asn Val Leu Asn Val Tyr Phe Val Lys Leu Ala		
	50	55 60
Trp Ala Trp Thr Phe Cys Leu Leu Leu Pro Phe Ile Ala Leu Thr Asn		
	65	70 75 80
Tyr His Leu Thr Gly Arg Ala Gly Leu Val Leu Arg Arg Leu Ser Thr		
	85	90 95
Leu Leu Val Gly Thr Ala Ile Trp Tyr Val Cys Thr Ala Ile Phe Ser		
	100	105 110
Asn Ile Glu Asp Tyr Thr Gly Ser Cys Tyr Gln Ser Pro Thr Leu Glu		
	115	120 125
Gly Val Arg Lys Glu His Gln Ser Lys Gln Gln Cys His Gly Glu Gly		
	130	135 140
Gly Phe Trp His Gly Phe Asp Ile Ser Gly His Ser Phe Leu Leu Thr		
	145	150 155 160
Phe Cys Ala Leu Met Ile Val Glu Glu Met Ala Val Leu His Glu Leu		
	165	170 175
Lys Met Asp Arg Ser His Cys Leu His Thr Ala Ile Thr Thr Leu Val		
	180	185 190
Val Ala Leu Gly Phe Leu Thr Phe Ile Trp Val Trp Met Phe Leu Cys		
	195	200 205

-continued

Thr Ala Val Tyr Phe His Asn Leu Ser Gln Lys Val Phe Gly Thr Leu
 210 215 220

Phe Gly Leu Leu Gly Trp Tyr Gly Thr Tyr Gly Phe Trp Tyr Leu Lys
 225 230 235 240

Ser Phe Ser Pro Gly Leu Pro Pro Gln Ser Ser Ser Leu Asn Leu Lys
 245 250 255

Gln Asp Ser Tyr Lys Lys
 260

<210> SEQ ID NO 16
 <211> LENGTH: 262
 <212> TYPE: PRT
 <213> ORGANISM: B.taurus
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: FIT2

<400> SEQUENCE: 16

Met Glu His Leu Glu Arg Cys Ala Trp Val Leu Arg Gly Thr Leu Val
 1 5 10 15

Arg Ser Ala Val Arg Lys Tyr Leu Pro Trp Ala Leu Ala Ala Ser Met
 20 25 30

Leu Ala Gly Ser Leu Leu Lys Glu Leu Ser Pro Leu Pro Glu Ser Tyr
 35 40 45

Leu Ser Asn Lys Arg Asn Val Leu Asn Val Tyr Phe Val Lys Val Ala
 50 55 60

Trp Ala Trp Thr Phe Cys Leu Leu Leu Pro Phe Ile Ala Leu Thr Asn
 65 70 75 80

Tyr His Leu Thr Gly Lys Ala Gly Leu Val Leu Arg Arg Leu Ser Thr
 85 90 95

Leu Leu Val Gly Thr Ala Ile Trp Tyr Val Cys Thr Ala Ile Phe Ser
 100 105 110

Asn Ile Glu His Tyr Thr Gly Ser Cys Tyr Gln Ser Pro Ala Leu Glu
 115 120 125

Gly Glu Arg Lys Glu His Gln Ser Lys Gln Gln Cys His Gly Glu Gly
 130 135 140

Gly Phe Trp His Gly Phe Asp Ile Ser Gly His Ser Phe Leu Leu Thr
 145 150 155 160

Phe Cys Ala Leu Met Ile Val Glu Glu Met Ala Val Leu His Glu Val
 165 170 175

Lys Thr Asp Arg Asn His Cys Leu His Ala Ala Ile Thr Thr Leu Val
 180 185 190

Val Ala Leu Gly Phe Leu Thr Phe Ile Trp Val Trp Met Phe Leu Cys
 195 200 205

Thr Ala Val Tyr Phe His Asn Leu Ser Gln Lys Val Phe Gly Thr Leu
 210 215 220

Phe Gly Leu Leu Gly Trp Tyr Gly Thr Tyr Gly Cys Trp Tyr Leu Lys
 225 230 235 240

Ser Phe Ser Pro Gly Leu Pro Pro Gln Ser Ser Ser Leu Asn Leu Lys
 245 250 255

Gln Asp Thr Tyr Lys Lys
 260

<210> SEQ ID NO 17

-continued

```

<211> LENGTH: 300
<212> TYPE: PRT
<213> ORGANISM: P.troglodytes
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: FIT1

<400> SEQUENCE: 17

Met Asp Lys Asp Ser Pro Glu Gln Leu Ala Leu Arg Tyr Glu Leu Glu
1          5          10          15

His Gly Pro Gly Ala Arg Ala Arg Ile Gln Ala Leu Leu Asp Cys Leu
          20          25          30

Val Lys Val Leu Leu Trp Val Ala Ser Ala Leu Leu Tyr Phe Gly Ser
          35          40          45

Glu Gln Ala Ala Arg Leu Leu Gly Ser Pro Cys Leu Arg Arg Leu Tyr
          50          55          60

His Ala Trp Leu Ala Ala Val Val Ile Phe Gly Pro Leu Leu Gln Phe
65          70          75          80

His Val Asn Pro Arg Thr Ile Phe Ala Ser His Gly Asn Phe Phe Asn
          85          90          95

Ile Lys Phe Val Asn Ser Ala Trp Gly Trp Thr Cys Thr Phe Leu Gly
          100          105          110

Gly Phe Val Leu Leu Val Val Phe Leu Ala Thr Arg Arg Val Ala Val
          115          120          125

Thr Ala Arg His Leu Ser Arg Leu Val Val Gly Ala Ala Val Trp Arg
          130          135          140

Gly Ala Gly Arg Ala Phe Leu Leu Ile Glu Asp Leu Thr Gly Ser Cys
145          150          155          160

Phe Glu Pro Leu Pro Gln Gly Leu Leu Leu His Glu Leu Pro Asp Arg
          165          170          175

Arg Ser Cys Leu Ala Ala Gly His Gln Trp Arg Gly Tyr Thr Val Ser
          180          185          190

Ser His Thr Phe Leu Leu Thr Phe Cys Cys Leu Leu Met Ala Glu Glu
          195          200          205

Ala Ala Val Phe Ala Lys Tyr Leu Ala His Gly Leu Pro Ala Gly Ala
          210          215          220

Pro Leu Arg Leu Val Phe Leu Leu Asn Val Leu Leu Leu Gly Leu Trp
225          230          235          240

Asn Phe Leu Leu Leu Cys Thr Val Ile Tyr Phe His Gln Tyr Thr His
          245          250          255

Lys Val Val Gly Ala Ala Val Gly Thr Phe Ala Trp Tyr Leu Thr Tyr
          260          265          270

Gly Ser Trp Tyr His Gln Pro Trp Ser Pro Gly Ser Pro Gly His Gly
          275          280          285

Leu Phe Pro Arg Pro His Ser Ser Arg Lys His Asn
          290          295          300

<210> SEQ ID NO 18
<211> LENGTH: 292
<212> TYPE: PRT
<213> ORGANISM: C.familiaris
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: FIT1

<400> SEQUENCE: 18

```

-continued

```

Met Glu Arg Gly Pro Ala Val Gly Ala Gly Leu Gly Ala Gly Ala Arg
1      5      10      15
Ile Arg Ala Leu Leu Gly Cys Leu Val Lys Val Leu Leu Trp Val Ala
20     25     30
Ser Ala Leu Leu Tyr Phe Gly Ser Glu Gln Ala Ala Arg Leu Leu Gly
35     40     45
Ser Pro Cys Leu Arg Arg Leu Tyr His Ala Trp Leu Ala Ala Val Val
50     55     60
Ile Phe Gly Pro Leu Leu Gln Phe His Val Asn Pro Arg Thr Ile Phe
65     70     75     80
Ala Ser His Gly Asn Phe Phe Asn Ile Lys Phe Val Asn Ser Ala Trp
85     90     95
Gly Trp Thr Cys Thr Phe Leu Gly Gly Phe Val Leu Leu Val Val Phe
100    105    110
Leu Ala Thr Arg Arg Val Ala Val Thr Ala Arg His Leu Ser Arg Leu
115    120    125
Val Val Gly Ala Ala Val Trp Arg Gly Ala Gly Arg Ala Phe Leu Leu
130    135    140
Ile Glu Asp Leu Thr Gly Ser Cys Phe Glu Pro Leu Pro Gln Gly Leu
145    150    155    160
Leu Leu His Glu Leu Pro Asp Arg Arg Ser Cys Leu Ala Ala Gly His
165    170    175
Gln Trp Arg Gly Tyr Thr Val Ser Ser His Thr Phe Leu Leu Thr Phe
180    185    190
Cys Cys Leu Leu Met Ala Glu Glu Ala Ala Val Phe Ala Lys Tyr Leu
195    200    205
Ala His Gly Leu Pro Ala Gly Ala Pro Leu Arg Leu Val Phe Leu Leu
210    215    220
Asn Val Leu Leu Leu Gly Leu Trp Asn Phe Leu Leu Leu Cys Thr Val
225    230    235    240
Ile Tyr Phe His Gln Tyr Thr His Lys Val Val Gly Ala Ala Val Gly
245    250    255
Thr Phe Ala Trp Tyr Leu Thr Tyr Gly Ser Trp Tyr His Gln Ser Trp
260    265    270
Ser Pro Gly Ser Pro Gly His Gly Leu Phe Pro Arg Pro His Ser Ser
275    280    285
Arg Lys His Asn
290

```

```

<210> SEQ ID NO 19
<211> LENGTH: 292
<212> TYPE: PRT
<213> ORGANISM: B.taurus
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: FIT1

```

```

<400> SEQUENCE: 19

```

```

Met Glu Arg Gly Pro Val Val Gly Ala Gly Arg Gly Ala Gly Ala Arg
1      5      10      15
Ile Arg Ala Leu Leu Gly Gly Leu Val Arg Val Leu Leu Trp Val Ala
20     25     30
Ser Ala Leu Leu Tyr Phe Gly Ser Glu Gln Ala Ala Arg Leu Leu Gly

```

-continued

35					40					45					
Ser	Pro	Cys	Leu	Arg	Arg	Leu	Tyr	His	Ala	Trp	Leu	Ala	Ala	Val	Val
50					55					60					
Ile	Phe	Gly	Pro	Leu	Leu	Gln	Phe	His	Val	Asn	Pro	Arg	Thr	Ile	Phe
65					70					75					80
Ala	Ser	His	Gly	Asn	Phe	Phe	Asn	Ile	Lys	Phe	Val	Asn	Ser	Ala	Trp
				85					90					95	
Gly	Trp	Thr	Cys	Thr	Phe	Leu	Gly	Gly	Phe	Val	Leu	Leu	Val	Val	Phe
			100					105					110		
Leu	Ala	Thr	Arg	Arg	Val	Ala	Val	Thr	Ala	Arg	His	Leu	Ser	Arg	Leu
			115					120					125		
Val	Val	Gly	Ala	Ala	Val	Trp	Arg	Gly	Ala	Gly	Arg	Ala	Phe	Leu	Leu
			130					135					140		
Ile	Glu	Asp	Leu	Thr	Gly	Ser	Cys	Phe	Glu	Pro	Leu	Pro	Gln	Gly	Leu
145					150					155					160
Leu	Leu	His	Glu	Leu	Pro	Asp	Arg	Arg	Ser	Cys	Leu	Ala	Ala	Gly	His
			165						170					175	
Gln	Trp	Arg	Gly	Tyr	Thr	Val	Ser	Ser	His	Thr	Phe	Leu	Leu	Thr	Phe
			180						185					190	
Cys	Cys	Leu	Leu	Met	Ala	Glu	Glu	Ala	Ala	Val	Phe	Ala	Lys	Tyr	Leu
			195					200					205		
Ala	His	Gly	Leu	Pro	Ala	Gly	Ala	Pro	Leu	Arg	Leu	Val	Phe	Leu	Leu
			210					215					220		
Asn	Val	Leu	Leu	Leu	Gly	Leu	Trp	Asn	Phe	Leu	Leu	Leu	Cys	Thr	Val
225					230					235					240
Ile	Tyr	Phe	His	Gln	Tyr	Thr	His	Lys	Val	Val	Gly	Ala	Ala	Val	Gly
			245						250					255	
Thr	Phe	Ala	Trp	Tyr	Leu	Thr	Tyr	Gly	Ser	Trp	Tyr	His	Gln	Pro	Trp
			260						265					270	
Ser	Pro	Gly	Ser	Pro	Gly	His	Gly	Leu	Phe	Pro	Arg	Pro	His	Ser	Ile
			275					280					285		
His	Lys	His	Asn												
			290												

<210> SEQ ID NO 20

<211> LENGTH: 47

<212> TYPE: DNA

<213> ORGANISM: artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: shRNA control

<400> SEQUENCE: 20

cacccaattc tccgaacgtg tcacgcgaac gtgacacgtt cggagaa

47

<210> SEQ ID NO 21

<211> LENGTH: 50

<212> TYPE: DNA

<213> ORGANISM: artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: shRNA FIT2

<400> SEQUENCE: 21

cacccaccca tgtttggttt gttggcgaac caacaaacca aacatggtgc

50

<210> SEQ ID NO 22

-continued

<211> LENGTH: 76
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 22

cattagcccc tctcagcct ccagcagagc agacagttag tggggagggg ccatggccga 60
tcatattcaa taaccc 76

<210> SEQ ID NO 23
<211> LENGTH: 69
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 23

tgtttgcgca ttgagcggga tcgaggaag agcccgtagg ctgggatccc ataacttcgt 60
atagcatac 69

<210> SEQ ID NO 24
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 24

gttgaccgtc agtcctcaaa ctggcccctt gc 32

<210> SEQ ID NO 25
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 25

gcttggtgg acgtaaaactc ctcttcagac c 31

<210> SEQ ID NO 26
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 26

gaaaagaatc ggaggagaca gagccaggcc tgg 33

<210> SEQ ID NO 27
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 27

gaaccagctg gggctcgact agagcttgcg g 31

<210> SEQ ID NO 28

-continued

<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 28

acacaagttt tgcacagaca tagatgcagg 30

<210> SEQ ID NO 29
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 29

caacttcaca cagcctagaa tcattctgaga ggagaacc 38

<210> SEQ ID NO 30
<211> LENGTH: 73
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 30

acacaagttt tgcacagaca tagatgcagg taaaatatac ataagtaagc gaacaactcc 60

gccgcgcgcg ctc 73

<210> SEQ ID NO 31
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 31

caacttcaca cagcctagaa tcattctgaga ggagaacctc aatggaggaa gagtaaactt 60

ggtctgacag 70

<210> SEQ ID NO 32
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 32

caggctgctc ttcaggagta tatctgggtt c 31

<210> SEQ ID NO 33
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 33

ccgggagcca ctttcttctc caaccgtccc gg 32

<210> SEQ ID NO 34

-continued

<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 34
agttacagac aattgtgagt tgccatgtgg c 31

<210> SEQ ID NO 35
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 35
ctgagatagg tgcctcactg attaagcatt gg 32

<210> SEQ ID NO 36
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 36
gtaccccaca gtcacatcca taggacaatc c 31

<210> SEQ ID NO 37
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 37
ctaactgtct gctctgctgg aggctgagga gg 32

<210> SEQ ID NO 38
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 38
gctcagagga ggcagacatg gcagatgttg ctgtatctgg cctaataaac ccgatcatat 60
tcaataaccc 70

<210> SEQ ID NO 39
<211> LENGTH: 69
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 39
acgtgggaat cctattagcc attgtcctcc tgcctcatg tccttctctt ataacttcgt 60
atagcatac 69

<210> SEQ ID NO 40

-continued

<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 40

taagaataga gtgtaagggt ggtagttggt cc 32

<210> SEQ ID NO 41
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 41

ccttcacctt tccccactcg tagtggtggt tc 32

<210> SEQ ID NO 42
<211> LENGTH: 73
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 42

acagtcacag ctcccatggc actcctcact gtaaatataa ctgcgcgatg gaacaactcc 60

gccgcgcgcg ctc 73

<210> SEQ ID NO 43
<211> LENGTH: 70
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 43

gctggcctgg aactcacttt atagagaggg ctgggtttga acctgtgttg gagtaactt 60

ggtctgacag 70

<210> SEQ ID NO 44
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 44

cttcgtgcac actagtcaag catcctacca ac 32

<210> SEQ ID NO 45
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 45

ctatatttgaa acaggatctc ttacgtgacc c 31

<210> SEQ ID NO 46

-continued

<211> LENGTH: 62
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 46

taatgaacca ggagcccagc agcctggcac gccaatgtt taggggtagc gatatcgaat 60
tc 62

<210> SEQ ID NO 47
<211> LENGTH: 62
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 47

gaaaaaaaga aagaaagaaa gcgagcaagc tttagttcaa gctacaagac agtggatcca 60
cc 62

<210> SEQ ID NO 48
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 48

accacatggt ggctcataac catctgtcat g 31

<210> SEQ ID NO 49
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 49

taagaataga gtgtaagggt ggtagttggt cc 32

<210> SEQ ID NO 50
<211> LENGTH: 62
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 50

acaagcttag ttggcagact ctgctggcgg tgccaccatg ttgccagcag gatatcgaat 60
tc 62

<210> SEQ ID NO 51
<211> LENGTH: 62
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 51

acgatgaggc aggetgctct cctctgctg agcctcagct ctcctctgag agtggatcca 60

-continued

cc	62	
 <210> SEQ ID NO 52 <211> LENGTH: 31 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Primer <400> SEQUENCE: 52 agtgagttcc agaacacgca gggctacaca g		31
 <210> SEQ ID NO 53 <211> LENGTH: 33 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Primer <400> SEQUENCE: 53 gctcagcaga gggagagcag cctgcctgat cgt		33
 <210> SEQ ID NO 54 <211> LENGTH: 4823 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Plasmid <400> SEQUENCE: 54 ttaatatttt gttaaaatc gcgttaaatt ttgttaaat cagctcattt ttaaccaat		60
aggccgaat cggcaaaatc cttataaat caaaagaata gaccgagata gggttgagt	120	
ttgttcagc ttggaacaag agtccactat taaagaacgt ggactccaac gtcaaagggc	180	
gaaaaaccgt ctatcagggc gatggcccac tacgtgaacc atcacctaa tcaagttttt	240	
tggggtcgag gtgcccgtaa gcactaaatc ggaaccctaa agggagcccc cgatttagag	300	
cttgacgggg aaagccggcg aacgtggcga gaaaggaagg gaagaaagcg aaaggagcgg	360	
gcgctagggc gctggaagt gtagcggta cgctgcgctg aaccaccaca ccgcgcgcgc	420	
ttaatgcgcc gctacagggc gcgtcagggt gcacttttcg gggaaatgtg cgcggaaccc	480	
ctatttgttt atttttctaa atacattcaa atatgtatcc gctcatgaga caataaccct	540	
gataaatgct tcaataatat tgaaaaagga agagtatgag tattcaacat ttccgtgtcg	600	
cccttattcc cttttttgcg gcattttgccc ttctgtttt tgctcaccca gaaacgctgg	660	
tgaaagtaaa agatgctgaa gatcagttgg gtgcacgagt gggttacatc gaactggatc	720	
tcaacagcgg taagatcctt gagagttttc gccccgaaga acgttttcca atgatgagca	780	
cttttaaaagt tctgctatgt ggccgggtat tatcccgtat tgacgccggg caagagcaac	840	
tcggtcgccg catacactat tctcagaatg acttggttga gtactacca gtcacagaaa	900	
agcatcttac ggatggcatg acagtaagag aattatgcag tgctgccata accatgagt	960	
ataacactgc ggccaactta cttctgacaa cgatcggagg accgaaggag ctaaccgctt	1020	
ttttgcacaa catgggggat catgtaactc gccttgatcg ttgggaaccg gagctgaatg	1080	
aagccatacc aaacgacgag cgtgacacca cgatgcctgt agcaatggca acaacgttgc	1140	
gcaaaactatt aactggcgaa ctacttactc tagcttcccg gcaacaatta atagactgga	1200	

-continued

tggaggcgga taaagttgca ggaccacttc tgcgctcggc ccttcgggt ggctgggtta	1260
ttgctgataa atctggagcc ggtgagcgtg ggtctcggcg tatcattgca gcactggggc	1320
cagatggtaa gccctccgt atcgtagtta tctacacgac ggggagtcag gcaactatgg	1380
atgaacgaaa tagacagatc gctgagatag gtgcctcact gattaagcat tggtaactgt	1440
cagaccaagt ttactcatat atactttaga ttgatttaaa acttcatttt taatttaaaa	1500
ggatctaggt gaagatcctt ttgataatc tcatgaccaa aatccctaa cgtgagtttt	1560
cgttccactg agcgtcagac cccgtagaaa agatcaaagg atcttctga gatccttttt	1620
ttctgcgcgt aatctgctgc ttgcaaaaa aaaaaccacc gctaccagcg gtgggttggt	1680
tgccggatca agagctacca actctttttc cgaagtaac tggcttcagc agagcgaga	1740
taccaaatac tgttcttcta gtgtagccgt agttaggcca ccacttcaag aactctgtag	1800
caccgcctac atacctcgt ctgctaatec tgttaccagt ggctgctgcc agtggcgata	1860
agtcgtgtct taccgggttg gactcaagac gatagttacc ggataaggcg cagcggtcgg	1920
gctgaacggg gggttcgtgc acacagccca gcttgagcgc aacgacctac accgaactga	1980
gatacctaca gcgtgagcta tgagaaagcg ccacgcttcc cgaagggaga aaggcggaca	2040
ggtatccggt aagcggcagc gtcggaacag gagagcgac gagggagctt ccagggggaa	2100
acgcctggta tctttatagc cctgtcgggt ttcgccacct ctgacttgag cgtcgatttt	2160
tgtgatgtc gtcagggggg cggagcctat ggaaaaacgc cagcaacgcg gcctttttac	2220
ggttcctggc cttttgctgg ccttttgctc acatgttctt tctgcgtta tccctgatt	2280
ctgtggataa ccgtattacc gcctttgagt gagctgatac cgctcgcgc agccgaacga	2340
ccgagcgag cgagtcagtg agcgaggaag cggagagcgc cccaatacgc aaaccgcctc	2400
tccccgcgcg ttggccgatt cattaatgca gctggcacga cagggttccc gactggaaag	2460
cgggcagtg ggcgaacgca attaatgtga gttagctcac tcattaggca cccaggtt	2520
tacactttat gcttccggt cgtatgtgt gtggaattgt gagcgataa caatttcaca	2580
caggaaacag ctatgaccat gattacgcca agctcgaaat taaccctcac taaagggaac	2640
aaaagctggt accgggcccc ccctcgaggt cgacctgcag ccaagctatc gaattcctgc	2700
agcccaattc cgatcatatt caataacct taatataact tcgtataatg tatgtatac	2760
gaagtatta ggtctgaaga ggagtttacg tccagccaag ctgacttggc tgcaggtcgt	2820
cgaattcta ccgggtaggg gaggcgctt tcccaaggca gtctggagca tgcgcttag	2880
cagccccgt gggcacttgg cgctacacaa gtggcctctg gcctcgaca cattccacat	2940
ccaccggtag gcgccaaccg gctcgttct ttgggtggcc cttcgcgcca ccttctactc	3000
ctccctagt caggaagttc cccccgcc cgagctcgc gtcgtgcagg acgtgacaaa	3060
tggagtagc acgtctcact agtctcgtgc agatggacag caccgctgag caatggaagc	3120
gggtaggcct ttggggcagc ggccaatagc agctttgtc cttcgtttc tgggctcaga	3180
ggctgggaag ggtgggtcc gggggcggc tcagggcgcg gctcagggc ggggcggcg	3240
cccgaaggtc ctccggaggc ccggcattct gcacgcttca aaagcgcacg tctgccgcgc	3300
tgttctctc tctctcatc ccgggcttct cgacctgcag cctgttgaca attaatcatc	3360
ggcatagtat atcggcatag tataatacga caaggtgagg aactaaacca tgggacggc	3420
cattgaacaa gatggattgc acgcaggttc tccggcgcgt tgggtggaga ggctattcgg	3480

-continued

ctatgactgg gcacaacaga caatcggtg ctctgatgcc gccgtgttcc ggctgtcagc	3540
gcagggggcgc ccggttcttt ttgtcaagac cgacctgtcc ggtgccctga atgaactgca	3600
ggacgaggca gcgcggctat cgtggctggc cagcagggc gttccttgcg cagctgtgct	3660
cgacgttgtc actgaagcgg gaagggactg gctgctattg ggcgaagtgc cggggcagga	3720
tctcctgtca tctcaccttg ctctgcccga gaaagtatcc atcatggctg atgcaatgcg	3780
gcggtgcat acgcttgatc cggctacctg cccattcgac caccaagcga aacatcgcat	3840
cgagcgagca cgtactcgga tggaaagcgg tcttgctgat caggatgatc tggacgaaga	3900
gcatcagggg ctgcgccacg ccgaactgtt cgcagggctc aaggcgcgca tgcccagcgg	3960
cgatgatctc gtcgtgacct atggcgatgc ctgcttgccg aatatcatgg tggaaaatgg	4020
ccgcttttct ggattcatcg actgtggcgc gctgggtgtg gcggaccgct atcaggacat	4080
agcgttggtt acccgtgata ttgtgaaga gcttgccggc gaatgggctg accgcttct	4140
cgtgctttac ggtatcgccg ctcccgattc gcagcgcacg gccttctatc gccttcttga	4200
cgagttcttc tgaggggata aattctctag agctcgctga tcagcctcga ctgtgccttc	4260
tagttgccag ccatctgttg tttgccctc ccccgctcct tccttgacct tggaaaggctc	4320
cactcccact gtcttttctt aataaaatga ggaaattgca tcgcattgtc tgagtaggtg	4380
tcattctatt ctgggggggtg ggggtgggca ggacagcaag ggggaggatt gggaaagaaa	4440
tagcaggcat gctggggatg cgggtgggctc tatggcttct gaggcggaaa gaaccagctg	4500
gggctcgact agagcttgcg gaacccttaa tataacttcg tataatgtat gctatacgaa	4560
gttattaggt cctcagaggg gatccactag ttctagagcg gccgccaccg cggtgagct	4620
ccaattcgcc ctatagttag tcgtattaca attcactggc cgtcgtttta caacgtcgtg	4680
actgggaaaa ccttgccgtt acccaactta atcgcttgc agcacatccc cctttcgcca	4740
gctggcgtaa tagcgaagag gcccgacccg atcgcccttc ccaacagttg cgcagcctga	4800
atggcgaatg gaaattgtaa gcg	4823

<210> SEQ ID NO 55

<211> LENGTH: 4832

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Plasmid

<400> SEQUENCE: 55

ctaaattgta agcgttaata ttttgttaaa attcgcgtta aatttttgtt aaatcagctc	60
attttttaac caataggccg aaatcggcaa aatcccttat aaatcaaaag aatagaccga	120
gataggggtg agtggtgttc cagtttgga caagagtcca ctattaaaga acgtggactc	180
caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg aaccatcacc	240
ctaatacagt tttttggggt cgaggtgccc taaagcacta aatcggaacc ctaaaggag	300
ccccgattt agagcttgac ggggaaagcc ggcgaaactg gcgagaaagg aagggaagaa	360
agcgaaagga gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac	420
cacaccgcc gcgcttaatg gcgcgtaca gggcgctcc cattcgccat tcaggtgctg	480
caactgttgg gaagggcgat cgggtcgggc ctcttcgcta ttacgccagc tggcgaaagg	540
gggatgtgct gcaaggcgat taagttgggt aacgccaggg ttttccagc cagcagctg	600

-continued

taaaacgacg gccagtgaat tgtaatacga ctactatag ggcgaattgg gtaccgggce	660
ccccctcgag gtgcacgcta tcgataagct tgatacgaa ttccgaagtt cctattctct	720
agaaagtata ggaacttcag gtctgaagag gaggtttacgt ccagccaagc tagcttggct	780
gcaggtcgtc gaaattctac cgggtagggg aggcgctttt cccaaggcag tctggagcat	840
gcgcttttagc agccccgctg ggcacttggc gctacacaag tggcctctgg cctcgcacac	900
attccacatc caccggtagg gcccaacggg ctccgttctt tggtagggccc ttcgcgcac	960
cttctactcc tcccctagtc aggaagtccc cccccgccc gcagctcgcg tctgcagga	1020
cgtgacaaat ggaagtagca cgtctcacta gtctcgtgca gatggacagc accgctgagc	1080
aatggaagcg ggtaggcctt tggggcagcg gccaatagca gctttgctcc ttcgctttct	1140
gggctcagag gctgggaagg ggtgggtccg ggggcgggct caggggcggg ctcagggcg	1200
gggcgggcgc ccgaaggtcc tccggaggcc cggcattctg cacgcttcaa aagcgacgt	1260
ctgcgcgct gttctctctc tctcatctc cgggccttcc gacctgcagc ctgttgacaa	1320
ttaatcatcg gcatagtata tcggcatagt ataatacgac aaggtaggga actaaacct	1380
gggatcggcc attgaacaag atggattgca cgcaggttct cggccgctt gggtaggag	1440
gctattcggc tatgactggg cacaacagac aatcggctgc tctgatgccg ccgtgttccg	1500
gctgtcagcg caggggcgccc cggttctttt tgtcaagacc gacctgtccg gtgccctgaa	1560
tgaactgcag gacgaggcag cgcggctatc gtggctggcc acgacggcg ttccttgcc	1620
agctgtgctc gacgttgtca ctgaagcggg aagggaactg ctgctattgg gcgaagtgcc	1680
ggggcaggat ctctgtcat ctcacctgc tctgcccag aaagtatcca tcatggctga	1740
tgcaatcggc cggctgcata cgcttgatcc ggctacctgc ccattcgacc accaagcgaa	1800
acatcgatc gagcgagcac gtactcggat ggaagccggt cttgtcgatc aggatgatc	1860
ggacgaagag catcaggggc tcgcgcagc cgaactgttc gccaggctca aggcgcgcat	1920
gcccgcggc gatgatctcg tcgtgaccca tggcgatgcc tgcttgccga atatcatggt	1980
ggaaaatggc cgcttttctg gattcatoga ctgtggccgg ctgggtgtgg cggaccgcta	2040
tcaggacata cggttggtta cccgtgatat tgctgaagag cttggcgcg aatgggctga	2100
ccgttctctc gtgctttacg gtatcgccg tcccattcg cagcgcatc ccttctatcg	2160
ccttcttgac gaggttctct gaggggatca attctctaga gctcgctgat cagcctcgac	2220
tgtgccttct agtgccagc catctgttgt ttgccctcc cccgtgcctt ccttgacct	2280
ggaaggtgcc actcccactg tcttttcta ataaatgag gaaattgcat cgcattgtct	2340
gagtaggtgt cattctatcc tgggggggtg ggtggggcag gacagcaagg gggaggattg	2400
ggaagacaat agcaggcatg ctggggatgc ggtgggctct atggcttctg aggcggaaa	2460
aaccagctgg ggctcgacta gagcttgccg aacccttcga agttcctatt ctctagaaa	2520
tataggaaat tcatacgta ggtacataat ataacttcgt ataagtatg ctatacgaag	2580
ttattagggt gatccactag ttctagagcg gccgccaccg cggtaggagc ccagcttttg	2640
ttccctttag tgagggttaa ttctgagctt ggcgtaatca tggctcatgc tgttctctgt	2700
gtgaaattgt tatccgctca caattccaca caacatacga gccggaagca taaagtgtaa	2760
agcctggggg gcctaagag tgagctaaat cacattaatt gcgttgccgt cactgcccgc	2820
ttccagtcg ggaacctgt cgtgccagct gcattaatga atcgccaac gcgcggggag	2880

-continued

aggcggtttg cgtattgggc gctcttcgc ttctcgcgc actgactgc tgcgctcgg	2940
cgttcggctg cggcgagcgg tatcagctca ctcaaaggcg gtaatacggg tatccacaga	3000
atcaggggat aacgcaggaa agaacatgtg agcaaaaggc cagcaaaagg ccaggaaccg	3060
taaaaaggcc gcgttgctgg cgtttttcca taggtccgc cccctgacg agcatcaca	3120
aatcgacgc tcaagtcaaa ggtggcgaaa cccgacagga ctataaagat accaggcgtt	3180
tccccctgga agctccctcg tgcgctctcc tgttcgacc ctgcgctta ccggatacct	3240
gtccgccttt ctcccttcgg gaagcgtggc gctttctcat agctcagct gtaggtatct	3300
cagttcgggt taggtcgttc gctccaagct gggctgtgtg cacgaacccc ccgttcagcc	3360
cgaccgctgc gccttatccg gtaactatcg tcttgagtc aaccggtaa gacacgactt	3420
atcgccactg gcagcagcca ctggtaacag gattagcaga gcgaggtatg taggcgggtg	3480
tacagagttc ttgaagtggg ggcctaacta cggctacact agaagaacag tatttggtat	3540
ctgcgctctg ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt gatccggcaa	3600
acaaaccacc gctggtagcg gtggtttttt tgtttgcaag cagcagatta cgcgcagaaa	3660
aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc agtggaaaga	3720
aaactcacgt taagggattt tggatcatg attatcaaaa aggatcttca cctagatcct	3780
tttaaattaa aaatgaagtt ttaaatcaat ctaaagtata tatgagtaaa cttggtctga	3840
cagttaccaa tgcttaatac gtgaggcacc tatctcagcg atctgtctat ttcgttcac	3900
catagttgcc tgactccccc tcgtgtagat aactacgata cgggagggct taccatctgg	3960
ccccagtgc gcaatgatac cgcgagaccc acgctcaccg gctccagatt tatcagcaat	4020
aaaccagcca gccggaaggg ccgagcgagc aagtggctct gcaactttat ccgcctccat	4080
ccagtctatt aattgttgcc gggaagctag agtaagtagt tcgccagttat atagtttgcg	4140
caacgttggt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg gtatggettc	4200
atcagctcc ggttcccaac gatcaaggcg agttacatga tccccatgt tgtgcaaaaa	4260
agcggtagc tccttcggtc ctccgatcgt tgcagaagt aagttggccg cagtgttacc	4320
actcatggtt atggcagcac tgcataatc tcttactgct atgccatccg taagatgctt	4380
ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtagc ggcgaccgag	4440
ttgtctctgc ccggcgtaaa tacgggataa taccgcgcca catagcagaa ctttaaaagt	4500
gctcatcatt ggaacacgtt ctccggggcg aaaactctca aggatcttac cgtgttgag	4560
atccagttcg atgtaacca ctctgtgcacc caactgatct tcagcatctt ttactttcac	4620
cagcgtttct ggggtgagcaa aaacaggaag gcaaaatgcc gcaaaaaagg gaataagggc	4680
gacacggaaa tgggtgaatac tcatactctt cctttttcaa tattattgaa gcatttatca	4740
gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata aacaaatagg	4800
ggtccgcgc acatttcccc gaaaagtgc ac	4832

<210> SEQ ID NO 56

<211> LENGTH: 39

<212> TYPE: DNA

<213> ORGANISM: artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: primer

<400> SEQUENCE: 56

-continued

caccatggag catctggagc gctgcgagtg gttgttgcg 39

<210> SEQ ID NO 57
 <211> LENGTH: 35
 <212> TYPE: DNA
 <213> ORGANISM: artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: primer

<400> SEQUENCE: 57

ttatttcttg taactatctt gcttcaaatt caaac 35

<210> SEQ ID NO 58
 <211> LENGTH: 35
 <212> TYPE: DNA
 <213> ORGANISM: artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: primer

<400> SEQUENCE: 58

tttcttgtaa ctatcttgct tcaaattcaa actac 35

1. A method of reducing fat storage in a tissue in a subject by administering to the subject an amount of an agent that is effective to decrease the level of FIT1 and/or FIT2 in the tissue in the subject.

2. The method of claim 1, wherein the subject has a disease involving storage of cytoplasmic fat in droplets.

3. The method of claim 1, wherein the subject has one or more of obesity, diabetes, metabolic syndrome, fatty liver disease, steatosis, steatohepatitis, atherosclerosis, diabetic nephropathy, and hepatitis C infection.

4. The method of claim 1, wherein the level of FIT2 is decreased in adipose tissue in the subject.

5. The method of claim 4, wherein the subject loses body weight.

6. The method of claim 1, wherein the level of FIT1 and/or FIT2 is decreased in the heart, muscle or liver in the subject.

7. The method of claim 1, wherein the agent is an antisense molecule, a ribozyme, an RNA interference (RNAi) molecule, a short hairpin RNA (shRNA), an antibody or an aptamer.

8. A method of increasing fat storage in a tissue in a subject by administering to the subject an amount of an agent that is effective to increase the level of FIT1 and/or FIT2 in the tissue in the subject.

9. The method of claim 1, wherein the agent affects amino acids FLL, corresponding to amino acids 157 through 159 of mFIT2; amino acid L, corresponding to amino acid 164 of mFIT2; or amino acid E, corresponding to amino acid 169 of mFIT2.

10. A method of screening for a disorder involving regulation of fat storage in a tissue, the method comprising deter-

mining the level of expression or activity of FIT1 and/or FIT2 in a blood, fluid, tissue or cell sample from a subject, wherein alternation from normal of the level of expression or activity of FIT1 and/or FIT2 in the sample is indicative of a disorder involving regulation of fat storage in a tissue.

11-18. (canceled)

19. A method for screening for a candidate agent that can reduce fat storage in tissue by determining whether or not the agent is effective to decrease the level of FIT1 and/or FIT2 in tissue or cells, wherein the method comprises contacting the agent with cells or tissue that express FIT1 and/or FIT2, and wherein reduction in expression or activity of FIT1 and/or FIT2 is indicative that the agent is a candidate agent for decreasing fat storage in tissue.

20. A method for screening for a candidate agent that can increase fat storage in tissue by determining whether or not the agent is effective to increase the level of FIT1 and/or FIT2 in tissue or cells, wherein the method comprises contacting the agent with cells or tissue that express FIT1 and/or FIT2, and wherein an increase in expression or activity of FIT1 and/or FIT2 is indicative that the agent is a candidate agent for increasing fat storage in tissue.

21-26. (canceled)

27. A transgenic mammal in which FIT1 and/or FIT2 is overexpressed in one or more tissue.

28-34. (canceled)

35. A mammal that has been genetically altered so that expression of FIT1 and/or FIT2 is reduced in one or more tissue.

36-40. (canceled)

* * * * *

专利名称(译)	通过调节fit1和fit2调节脂滴形成及其用途		
公开(公告)号	US20100095391A1	公开(公告)日	2010-04-15
申请号	US12/448840	申请日	2008-01-08
[标]申请(专利权)人(译)	SILVER DAVID大号		
申请(专利权)人(译)	SILVER DAVID大号		
当前申请(专利权)人(译)	SILVER DAVID大号		
[标]发明人	SILVER DAVID L		
发明人	SILVER, DAVID L.		
IPC分类号	A01K67/00 A61K31/711 A61K31/7105 A61K39/395 G01N33/53 A61P3/04		
CPC分类号	A01K67/0275 G01N2800/085 A01K2217/052 A01K2217/075 A01K2217/206 A01K2227/105 A01K2267/0362 C12N15/113 C12N2310/11 C12N2310/12 C12N2310/14 C12N2310/16 G01N33/6893 G01N2500/10 G01N2800/044 A01K67/0276 A61P3/04		
优先权	60/880279 2007-01-12 US		
其他公开文献	US8129121		
外部链接	Espacenet USPTO		

摘要(译)

本发明提供了通过调节纤维诱导的转录物1 (FIT1) 和/或纤维诱导的转录物2 (FIT2) 的水平来调节组织中脂肪储存的方法, 以及涉及调节组织中脂肪储存的病症和病症的诊断筛选, 用于鉴定可以通过调节FIT1和/或FIT2水平来调节组织中脂肪储存的试剂的试验, 以及在一种或多种组织中改变FIT1和/或FIT2表达的遗传改变的哺乳动物。

